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Abstract 
Magnetic Resonance Imaging (MRI) is one of the most important diagnostic tools 
available in medicine. The specificity and sensitivity of MRI can be further enhanced by 
the introduction of contrast agents. As many clinically valuable targets reside inside the 
cell membrane, therefore, developing efficient intracellular targeted MR contrast agent is 
required. The objective of the present project is to construct novel targeted intracellular 
MR contrast agents aiming to image mRNA transcription by MRI. 
The first part of this thesis takes an effort to search for an optimal vector for the 
intracellular delivery of MR contrast agents. Eight intracellular MR contrast agents, 
which conjugate different cell-penetrating peptides (CPP) with FITC and Gd(III) 
complexes, were synthesized by a continuous solid phase synthesis scheme. The key 
intermediates and final products were characterized by ESI-MS. Relaxivities of these MR 
contrast agents were measured at a frequency of 123 MHz and a magnetic field of 3 T. 
The comparison studies of the uptake and toxicity on NIH/3T3 cells suggest that D-Tat57-
49 contrast agent could label cells sufficient to enhance significantly relaxation rates R1 
and R2 for MR measurements, thus D-Tat57-49 peptide proves to be a useful CPP for the 
development of new intracellular MR contrast agents. 
The second part of this thesis describes the design and synthesis of antisense MR contrast 
agents, which conjugate PNA with CPP, Gd-DOTA and FITC. The intracellular uptake 
was confirmed by fluorescence spectroscopy, fluorescence microscopy and MR imaging 
on NIH/3T3 mouse fibroblasts as well as on transgenic dsRed cells. A subtoxic labeling 
concentration of 0.5 µM is sufficient to enhance significantly MR imaging contrast. The 
intracellular Gd(III) contents are at the range of 10-9~10-8 mol Gd/107 cells. An in vitro 
PNA-DNA binding assay confirmed that there is a significant higher specificity of the 
dsRed antisense contrast agent in comparison to its non-sense counterpart. However, no 
specific accumulation of the antisense dsRed CA in comparison to the non-sense CA 
could be detected in the target containing dsRed cells. Fluorescence microscopy studies 
have showed an exclusive endosomal localization of the contrast agents. Thus, further 
modifications of the contrast agents are required to achieve the release from endosomes 
or a direct uptake into the cytosol. 
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Chapter 1. Introduction 
1.1 MR imaging and MR contrast agents 
Magnetic Resonance Imaging (MRI) is one of the most versatile imaging techniques 
based on the principles of nuclear magnetic resonance (NMR). With its excellent spatial 
resolution, noninvasive nature and so far unsurpassed ability in distinguishing soft 
tissues, MRI has therefore become one of the most important diagnosis tools available in 
medicine (1, 2). MRI offers high three-dimensional spatial resolution down to the 10-µm 
range (3, 4), complete body coverage, and the opportunity to determine additional 
physiologic parameters noninvasively (e.g., blood flow, perfusion, and diffusion). All 
these characterize MRI to contain considerable potential for molecular imaging (5). The 
MRI signal is created through the interaction of the total water signal (proton density) and 
the magnetic properties (T1: the longitudinal relaxation time, and T2: the transverse 
relaxation time) of the tissues being imaged. Differential contrast in soft tissues depends 
on endogenous differences in water content, relaxation times, and/or diffusion 
characteristics in the tissue of interest. T1 and T2 weighted images display the best 
contrast for soft tissues, as proton spin density is essentially invariant while relaxation 
times vary greatly from one tissue to the other (6, 7).  
Nevertheless, there remains the possibility of poor contrast between healthy and damaged 
tissue due to a too small variation in relaxation times. MR contrast agents are chemicals, 
which are able to enhance the relaxation rates of water protons (8). They are applied in 
MR imaging to increase the signal difference between the area of interest and the 
background. Indeed, the influence of MR contrast agents on the relaxation times of 
proton spins has a marked effect on the signal intensity thereby increasing the contrast of 
the images and better delineating the objective regions.  
MR contrast agents do not appear themselves on MR images but affect longitudinal and 
transverse relaxation of the surrounding nuclei, mainly the water solvent protons (9). The 
addition of a contrast agent results in an increased relaxation rate of the surrounding 
nuclei that appear as a bright spot of increased intensity in T1-weighted images or as a 
region of decreased brightness in T2-weighted images (10). MR contrast agents are thus 
classified as positive or negative, T1 or T2, contrast agents. The two major classes of MR 
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contrast agents are paramagnetic contrast agents, usually based on the chelates of Gd(III) 
generating T1 positive signal enhancement (11, 12), and super-paramagnetic contrast 
agents that use mono- or polycrystalline iron oxide to generate strong T2 negative 
contrast in MR images (13). 
Most of MR contrast agents, which have already approved for clinical use, are complexes 
of gadolinium (III) as this ion has a high magnetic moment and a long electronic 
relaxation time. The choice of Gd(III) would be expected, for no other ion has seven 
unpaired electrons. But there is a much more subtle reason it performs so well. The 
symmetric S-state of Gd(III) is a hospitable environment for electron spins, leading to a 
much slower electronic relaxation rate. In the intricate effect that gives rise to relaxivity, 
water protons hardly feel the effects of ions such as Dy(III); Gd(III) electrons, on the 
other hand, are more closely in tune with the proton’s frequency (10). Thus Gd(III) 
exhibits the strongest effect of all elements on the longitudinal relaxation time T1. Water 
exchanges quite readily on Gd(III) aqua complexes. The rate of exchange between aqua 
ligands on octadenatate-chelated Gd(III) is approximately 3 x 106 s-1, which allows 
thousands of water molecules to transiently coordinate to a single ion on the MRI time 
scale. Therefore, the effect of the metal fragment on relaxation times is widespread, and 
only low concentrations (0.1-0.3mmol/Kg) are necessary to be effective.  
Since T1 weighted protocols in MRI have rapid pulse sequences, the advances in MRI 
have strongly favored T1 agents and thus Gd(III) (10). Faster scans with higher resolution 
require more rapid radio frequency pulsing and are thus generally T1-weighted since the 
MR signal in each voxel becomes saturated. T1 agents relieve this saturation by restoring 
a good part of the longitudinal magnetization between pulses. At the same time, a good 
T1 agent would not significantly affect the bulk magnetic susceptibility of the tissue 
compartment in which it is localized, thus minimizing any inhomogeneities which can 
lead to image artifacts and/or decreased signal intensity. Small iron particles can function 
as T1 agents using very T1-weighted scans, but the resulting changes in magnetic 
susceptibility are much larger than that for Gd(III) chelates.  
However, since the free metal ion of Gd (III) being toxic, its complexation is needed in 
order to ensure the innocuousness of the agent during its travel through the body of the 
patient. Gadolinium chelate remains in the body several days after intravenous 
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administration. Coordinating the metal to ligands can reduce its toxicity if the chelates are 
too obstinate to be displaced by water (12). Currently, all Gd(III)-based chelates 
approved for clinic application in MRI are eight or nine-coordinated complexes. One or 
two coordination sites must be open for water molecules, to allow inner sphere spin 
transitions, or transitions between the metal nuclei and a ligand to which they are directly 
bound.  The formation of kinetically inert and thermodynamically stable complexes of 
Gd (III) has been demonstrated with chelating agents such as 
diethylenetriaminepentaacetic acid (DTPA) and 1,4,7,10-tetracarboxymethyl-1,4,7,10-
tetraazacyclododecane (DOTA) (Figure 1). The metal ion is buried in the cage, so it is 
unlikely to bind to donor groups in proteins and enzymes. There is nothing in the 
chemical structure of the ligand that a good nucleophile or electrophile can attack. They 
actually do remain chelated in the body and are excreted intact. Apparently, the off-the-
shelf ligands such as DTPA or DOTA form complexes strong enough so that, for the 
period that the agents are in the body, there is no detectable dissociation. This is in the 
face of significant amounts of phosphate, citrate, transferrin, and other chelating 
substances. Since the approval of [Gd (DTPA) (H2O)]2- in 1988, it can be estimated that 
gadolinium chelates have been administered to millions of patients worldwide. Currently, 
approximately 30% of MRI examinations include the use of contrast agents, and this is 
projected to increase as new agents and applications arise (10).  
              
N
N
NO
O
O
O
O
O
O O
O O
Gd
O
H H
[Gd(DTPA)(H2O)]2-  (MagnevistTM)              
N
N
N
N
O
O
O
O
O
O
O
O
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O
H H
[Gd(DOTA)(H2O)- (DotaremTM)    
Figure 1. Chemical structures of [Gd(DTPA)(H2O)]2- and [Gd(DOTA)(H2O)]- 
 
Iron-oxide-based contrast agents usually consist of a monocrystalline (MION) or small 
polycrystalline (SPIO) magnetic core with a diameter of 5 to 30 nm embedded with a 
polymer coating (such as dextran or other polysaccharides) for a total particle diameter of 
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17-50 nm, respectively. Generally, the relaxation properties of these contrast agents 
depend on the molecular size of the carrier and larger molecules have a higher relaxivity 
per molecule. Therefore to improve the sensitivity of detection, it is feasible to use large, 
highly efficient contrast agents. For example, SPIO particles can be detected at 
micromolar concentrations of iron, and offer sufficient sensitivity for T2-weighted 
imaging. On the other hand, the large molecular size can prevent effective extravasation 
of the contrast agent molecules from the vasculature, and reduce diffusion of the contrast 
agent through the interstitium (13, 14). 
These contrast agents discussed above are all non-specific, even if their distribution in the 
body is far from homogeneous, and their efficacy in enhancing contrast stems from their 
preferential distribution in the blood stream because they are all quite hydrophilic. 
Nonspecific contrast agents are widely available for clinical use. They show a 
nonspecific distribution pattern that allows measurement of tissue perfusion, vascular 
permeability, or vascular volume in a given voxel. These parameters can be extracted by 
fast imaging techniques and pharmacologic modeling or steady-state imaging techniques 
(15, 16). However, true molecular targets can not be imaged with this approach. Thus, 
there remains the need for novel compounds of improved performances. Increased 
efficacy, exclusive blood distribution, targeting, and sensing are some of the exciting 
properties of the new molecules developed in the last few years (17, 18). These novel MR 
contrast agents can be basically divided into smart and targeted probes according to their 
dynamic mechanism.  
Smart contrast agents might change MR signals, which depend on some variables in their 
immediate environment. Various stimuli, ranging from pH to enzymes, have been 
exploited for generating intelligent agents (19 - 21). The most important factor for 
obtaining an efficient smart contrast agent is that the percent change in relaxivity, and not 
its absolute value. Usually, smart contrast agents have been built on Gd(III) systems 
because their relaxivity can be dictated by their environment. The numbers of water 
molecules in the first coordination sphere, the water exchange rate and the rotational 
correlation time have a strong effect on the relaxivity of the compounds and can be 
influenced by many other factors.  
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Targeted MR contrast agents are linked to specific affinity ligands such as peptides, 
antibody fragments, or small molecules imparting molecular specificity to the probe. 
Combining efficient targeting strategies with sensitive imaging techniques may help to 
resolve molecular targets in the nanomolar range in vivo. Thus, the detection of cell 
surface proteins (e.g., tumor associated receptors) is feasible (22). Approaches to increase 
the sensitivity of MR with targeted contrast agents were presented by Wickline et al. (23) 
who significantly amplified the number of reporter molecule per nanoparticle (up to 
90,000 gadolinium chelates per nanoparticle). The nanoparticles can be targeted with 
high affinity to specific molecules via antibodies. This scheme was exploited for 
visualization of fibrin in vascular plaques and vascular expression of integrins in tumors 
(23). Other studies have reported targeted contrast agents for imaging Alzheimer amyloid 
plaques, the human transferrin receptor, and the secretin receptor or the endothelial 
integrin αvβ3 (24, 25). More recently, an antibody-conjugated gadolinium chelate was 
applied for in vivo MR imaging of HER-2/neu receptors in a mouse xenograft model (26, 
27). Biotinylated anti-HER-2/neu antibody was administered first followed by a 
gadolinium chelate complexed with avidin; the amplified R1 lengthening effect indicates 
that the agent is localized to tumor areas in which the HER-2/neu receptor is expressed.  
 
1.2 Labeling of cells with MR contrast agents 
Due to its high spatial resolution capabilities and excellent soft tissue contrast, MR 
imaging is excellently suited for cell tracking application. MRI contrast agents can be 
incorporated into cells by electroporation, and passive or active targeting mechanisms 
such as phagocytosis, pinocytosis, receptor mediated endocytosis, transporters, and cell 
penetrating peptide mediated intracellular uptake (28).  Passive targeting agents primarily 
highlight phagocytic cells and organs naturally responsible for particle clearance within 
the body. Active targeting refers to ligand-directed, site-specific accumulation of contrast 
and /or therapeutic agents. 
Electroporation has recently been used to label cells with Gd chelates and SPIO 
nanoparticles (29). Electroporation is commonly used to introduce DNA into the cell 
genome and is known to be associated with cell stress due to chemical imbalances and 
efflux or influx of chemicals from within the cell and surrounding media altering the cells 
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viability and survival. There is relatively little experience using this approach with MRI 
contrast agents to label cell, and it is unclear as to the long-term effects on reactive 
oxygen species (ROS) or cell viability when using this method. It has been demonstrated 
that a significant amount of cell lysis and death occurred during electroporation, and 
following labeling of contrast agents (30). 
Phagocytosis is a special form of endocytosis in which particles are ingested through the 
formation of a large endocytic vesicle. In principle this appears the route of choice for 
labeling cell endowed with efficient phagocytic activity, as it would allow single step 
internalization of large amount of contrast agent. Whereas the entrapment of iron oxide 
particles by this process is immediately effective in inducing marked change in MR 
contrast of labeled cells, in the case of Gd containing particles, it is necessary to foresee 
its further solubilization in order to fully exploit the potential of the imaging probe based 
on paramagnetic Gd-chelates (31). 
Pinocytosis, also called fluid endocytosis, is the process through which the cell entraps 
portions of the extracellular fluid by means of the progressive invaginations of the 
membrane, to form vesicles that evolve from early to late endosomes eventually to end 
up into lysosomes. Incubation of cells in a medium containing MR contrast agents at 
sufficiently high concentration leads to its internalization at amounts that may be 
sufficient for MR imaging (32).  
Receptor mediated endocytosis is the most widely applied scheme to internalize MR 
contrast agents into cells as it is expected to occur anytime a ligand is modified by 
attaching one or more metal-chelate moieties. Receptor mediated endocytosis is the 
mechanism of choice for the internalization of dendritic polymers containing a high 
number of Gd(III) complexes. The first example of receptor-mediated endocytosis of 
Gd(III) complexes dendritic polymers dealt with the targeting of tumor cells 
overexpressing the high affinity folate receptor (hRF) (33). It showed that the uptake of 
folate-conjugated dendrimers into cells occurs with a sigmoidal dose-responsive curve as 
expected for a specific uptake. Other samples of receptor-mediated endocytosis of MR 
contrast agent included β-D-galactose receptor, cholecystokinine receptor and 
somatostatin analogs. 
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Transporters’ scheme appears an interesting one as such systems are intrinsically devoted 
to cell internalization of large quantities of substrate molecules. Gd-DTPA-glutamine has 
been tested to differentiate tumor from healthy cells. After a few hours of incubation, the 
amount of Gd-chelate internalized in tumor cells is 4-5 times higher than that taken up by 
healthy hepatocytes (34). 
Cell penetrating peptides (CPPs) have been extensively utilized to achieve intracellular 
delivery (35-37). CPPs usually consist of short, typically basic, peptide sequences of 7–
34 amino acids in length that are capable of crossing the cell membrane either alone or 
attached to a molecular cargo. Early observations revealed that these cell-penetrating 
peptides rapidly translocate into various cell types. Included among such peptides are the 
third helix of the homeodomain of Antennapedia (38), polyarginines (39), guanidinium 
peptides (40), and viral proteins such as herpes simplex virus VP22 (41), HIV-1 Rev 
protein (42), and the basic domain of HIV-1 Tat protein (43). When administered in non-
toxic concentrations, CPPs can be used to transport genes, therapeutic drugs and 
diagnostic probes into the intracellular compartment. Although the exact mechanism for 
membrane translocation of CPPs remain under investigation, successful utilization of 
CPPs not only for molecular imaging, but also for therapeutic and combined applications, 
is progressing in numerous fields of research. 
Delivering imaging agents to intracellular compartments by peptides would allow for 
selective retention and signal amplification, thereby opening up a broad range of novel 
molecular imaging applications (44). CPPs have been explored to carry MR contrast 
agents into cells. Bhorade et al. reported that Gd-DOTA bound to HIV-Tat peptide is 
efficiently internalized into mammalian cells (45). For this application, DOTA is 
conjugated to a Lys C-terminally appended to Tat using orthogonal synthetic strategies 
and stably complexed with Gd under standard conditions (Figure 2). T1-weighted spin-
echo MR images of cells embedded in agar indicated the presence of enhanced 
intracellular relaxivity, consistent with transduction of Gd-DOTA-Tat peptide into the 
cell interior. The intracellular localization of the Gd complex was confirmed with a 
fluorescein-conjugated Tat peptide that showed cytosolic localization. Furthermore, 
intracellular delivery of the Gd-DOTA complex using other CPPs such as poly-Arg 
peptides has been reported (46). The permeation, relaxivity, and enhanced retention 
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properties of the Gd-DOTA poly-Arg peptide were well characterized in several cell 
types using inductively coupled plasma mass spectrometry (ICP-MS) and T1 relaxivity 
measurement (47).   
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Figure 2. CPP conjugated intracellular MR contrast agents  
 
The Tat peptide has also been used to mediate delivery of biocompatible cross-linked 
iron oxide particles (CLIO) and superparamagnetic nanoparticles into cells (48). The 
derivatized particles have been shown to internalize into mouse spleen lymphocytes 
greater than 100-fold more efficiently than nonmodified particles. By labeling CLIO 
particles with FITC, cytoplasmic and nuclear localization was demonstrated. CLIOs 
affect the transverse relaxation time (T2) by introducing large susceptibility effects, which 
alter the local magnetic field homogeneity and result in signal loss where CLIOs are 
located. The strong decrease in signal by MR imaging enables the magnetically labeled 
cells to be tracked in vivo. These results demonstrate that CPP can be used to ferry 
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magnetic particles efficiently into cells; and labeled cells can be visualized by MR 
imaging at the single-cell level in vitro and/or induce signal intensity changes detectable 
in whole organs (48). 
1.3 Antisense imaging  
Real-time imaging of gene expression in vivo at high spatial resolutions has been a long-
cherished goal in molecular research (49). If such techniques were available, both 
endogenous and exogenous (for example, gene therapy) expression could be studied in 
live animals and potentially in a clinical setting. Currently, the most widely used 
strategies for imaging gene expression are termed “direct” and “indirect” approaches 
(50). Direct molecular imaging can be defined in terms of a probe–target interaction, 
whereby the resultant image of probe localization and magnitude (image intensity) is 
directly related to its interaction with the target epitope or enzyme. A recent direct 
imaging strategy involves the development of antisense and aptamer oligonucleotide 
probes that specifically hybridize to target mRNA or proteins in vivo. Radiolabeled 
antisense probes (RASONs) have been developed to directly image endogenous gene 
expression at the transcriptional level. RASONs are small oligonucleotide sequences that 
are complementary to a small segment of target mRNA or DNA and could potentially 
target any specific mRNA or DNA sequence. In this context, imaging specific mRNAs 
with RASONs produces "direct" images of specific molecular-genetic events. Direct 
imaging of mRNA can provide information on cellular gene expression patterns and may 
have the potential to detect molecular changes in disease states at relatively early stages, 
providing opportunities for pre-emptive therapeutic interventions.  
The concept of using antisense molecules to inhibit gene expression was introduced in 
1967, as a result of the elucidation of the rules of Watson-Crick and Hoogsteen base pair 
formation between nucleic acids (51); the basis of this promise was that specific DNA or 
messenger RNA sequences could be arrested uniquely by relatively short complementary 
oligonucleotides for antigene or antisense therapy, respectively (Figure 3). The principles 
for application of antisense agents in antiviral and cancer therapy are now well defined 
(52). Theoretically, the same principles could serve as guidelines for the development of 
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labeled antisense oligonucleotide analogues for imaging gene expression. Therefore, 
antisense imaging should be highly specific from theoretical considerations. 
 
 
 
  
                   
Figure 3. Base pairing between purines and pyrimidines  
 
In 1994, Dewanjee produced the first non-invasive tumor image in a living animal model 
using a radiolabeled antisense oligonucleotide (53). Yet real-time, direct, in vivo imaging 
of endogenous gene expression has still not been demonstrated in a widespread and 
conclusive manner by this method. Various problems have exhibited such as: (i) low 
number of target mRNA/DNA molecules per cell; ii) limited tracer delivery (poor cell 
membrane and vascular permeability, cannot penetrate blood–brain barrier); (iii) poor 
stability (degradation by H-RNAse); (iv) slow clearance (slow washout of nonbound 
oligonucleotides); and (v) comparatively high background activity and low specificity of 
localization (low target/background ratios).  Recent developments in antisense imaging 
technology extend the possibility that this modality will become an extremely powerful 
tool for the noninvasive study of gene expression in vivo. These developments include: (i) 
new antisense analogues with superior properties for binding macromolecular nucleic 
acids, (ii) advances in radiolabeling chemistry to produce extremely high specific activity 
antisense imaging agents, (iii) novel drug targeting technology to improve in vivo 
specificity, and (iv) emerging optical imaging modalities for in vitro screening 
applications and real-time in vivo imaging of gene expression (54).  
The first antisense agents were DNAs, but these oligonucleotides are rapidly degraded by 
nucleases in vivo, greatly limiting their utility for imaging applications. A number of 
novel oligonucleotide analogues, designed for improved stability, target binding, and 
antisense activity, have been synthesized and evaluated in vitro and in vivo. 
Methylphosphonate DNA, Phosphorothioate DNA, 2’-O-methyl RNAs (55), PNAs 
(peptide nucleic acids) (56), MORFs (morpholino) (57), and HypNA-pPNAs (trans-4-
-A-T-G-C-
  
-U-A-C-G-
Antisense fragment
mRNA
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hydroxy-L-proline nucleic acid-phosphono nucleic acid) (58) (Figure 4) bind 
complementary RNA with greater affinity, stability, and mismatch specificity than 
corresponding DNA:RNA duplexes, potentially rendering them more suitable for 
antisense imaging.  
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Figure 4. General structures of some DNA and RNA analogues for antisense 
imaging 
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PNA is a DNA mimic containing a pseudopeptide backbone that makes it extremely 
stable in biological fluids. Despite the radical difference in the chemical composition of 
the backbone, PNA not only retains but also improves the hybridization characteristics of 
DNA and RNA. In most cases PNA oligomers with mixed bases sequences form 
duplexes (by Watson-Crick base-pairing) with complementary DNA and RNA with 
higher thermal stability than corresponding DNA-DNA or DNA-RNA complexes and 
without sacrificing sequence specificity (59). These qualities make PNA a leading agent 
among ‘third generation’ antisense and antigene agents (60). For example, Pardridge et 
al. (61) reported the imaging of gene expression in the brain in vivo by a PNA-antisense 
probe. They synthesized an antisense-imaging agent comprised of an radio-iodinated 
PNA conjugated to a monoclonal antibody to the rat transferrin receptor by using avidin-
biotin technology. The PNA is a 16-mer antisense to the sequence around the methionine 
initiation codon of the luciferase mRNA. The PNA conjugate was injected intravenously 
in animals with brain tumors and which were killed 2h later for frozen sectioning of brain 
and film autoradiography. Tumors were imaged in all rats administered the [125I] labeled 
PNA that was antisense to the luciferase sequence. This study demonstrated that gene 
expression in the brain in vivo could be imaged with antisense radiopharmaceuticals that 
are conjugated to a brain drug-targeting system.  
Tian et al. (62) also designed an antisense PNA probe, which conjugated PNA with an 
IGF1 peptide on the C-terminus, and a [99mTc] chelator on the N-terminus. The PNA is a 
12-mer antisense to the sequence of the MYC mRNA. MCF7 xenografts in nude mice 
were visualized at 4 and 24h after tail vein administration of the [99mTc] PNA probe 
specific for MYC mRNA, but not with the mismatch control.  
These results demonstrated that molecular imaging of oncogene mRNA in solid tumors 
with antisense PNA-peptide chimeras might provide additional genetic characterization 
of pre-invasive and invasive cancers.  
Although there are a lot of publications which reported to image gene expression by radio 
labeled antisense imaging, MRI imaging of gene expression are usually achieved by two 
approaches: (i) imaging of introduced reporters or enzymes, which bind or metabolize 
paramagnetic substrates; or (ii) imaging of a unique spectroscopic signature (63). 
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Developing the antisense conjugated MRI contrast agent will propose a new method to 
image gene expression in vivo. In addition, development of targeted MR contrast agent 
directed to specific molecular entities could dramatically expand the range of MR 
applications by combining the noninvasiveness and high spatial resolution of MRI with 
specific localization of molecular targets. 
In 2003, Heckl et al. (64) reported the first and to date the only results on an intracellular 
MR contrast agent, composed of a gadolinium complex, a c-myc-specific PNA sequence 
and a transmembrane carrier peptide, showing the potential of tracking cells in vivo by 
MRI using mRNA as target. In MR imaging, increased intracellular signal intensity in 
HeLa cells could be detected after just 10 min of incubation with Gd3+-complex and 
subsequently reached a maximum after 1h. This rapid increase in signal intensity after 10 
min was also observed in vivo in Dunning prostate tumors independent of the specificity 
of PNA, and subsequently, reaching a maximum after 30 min. However, there is no 
further study reported. Whether improvements on this strategy can be achieved using 
different carrier peptides and/or contrast agent moieties remains an important question. 
 
1.4 Synthesis schemes of PNA-peptide conjugates 
The main hindrance to the effective use of PNA oligomers has been their relatively poor 
uptake by cells. A great deal of effort has gone into devising means for enhancing the 
intracellular delivery of oligonucleotides (65, 66), including viral vectors, cationic lipids 
and cationic liposomes. Although cationic lipids and polymer carriers have been widely 
used in the laboratory setting, a new approach involving conjugation of oligonucleotides 
to peptide vectors seems particularly promising. Peptide-oligonucleotide conjugates (67), 
unlike oligonucleotide complexes with cationic lipids or polymers, are of relatively 
modest molecular size. Thus, they are more likely to evade uptake by the phagocytes of 
the reticuloendothelial system and to attain a widespread biodistribution subsequent to in 
vivo administration.  
Two different strategies have been adopted for the synthesis of PNA-peptide conjugates: 
On-line continuous solid-phase synthesis schemes and fragment conjugation schemes 
(68). 
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 During continuous solid-phase synthesis scheme, PNA-peptide conjugates are 
synthesized by adaptation of established solid-phase peptide synthesis protocols (69). 
Commercially available PNA monomers have their back-bone amine group protected 
with either the 9-fluorenyl-methoxycarbonyl (Fmoc) or N-tert-butoxycarbonyl (Boc) 
group, while the exocyclic amines of the nucleobases (A, C and G) are protected by the 
benzhydryloxycarbonyl (Bhoc) or Benzyloxycarbonyl (Z) protecting groups. The solid-
phase synthesis of a peptide-C-terminal to N-terminal-PNA conjugate commences with 
the immobilization of a PNA monomer to an acid labile linker on a suitable resin. 
Usually, the polyethyleneglycol-polystyrene (PEG-PS, linker=rink amide) resin can be 
used for Fmoc/Bhoc chemistry synthesis scheme; whereas the PS resin (linker = 
methylbenzhydrylamine) resin is compatible with Boc/Z chemistry synthesis scheme. 
Removal of the N-terminal protecting group (with 20% piperidine/ DMF for Fmoc or 
50% TFA for Boc, is followed by elongation with the next protected building block under 
the agency of a coupling reagent (e.g. HATU) and capping of residual amines with acetic 
anhydride, which leads to a PNA dimer. Repetition of this reaction cycle entailing 
deprotection, coupling and capping steps eventually leads to the construction of an 
immobilized fully protected PNA-peptide conjugate. End-capping of this construct 
(removal of the final protecting group and acetylation of the N-terminus) is carried to 
prevent the formation of PNA rearrangement or breakdown products. Finally, cleavage 
from the resin and deblocking of the protecting groups (TFA in the presence of 
scavengers (Fmoc); HF or 10% TFMSA/TFA and scavengers (Boc)) affords the target 
peptide-PNA conjugate.  
In the fragment conjugation scheme, PNA oligomer and peptide oligomer are assembled 
separately on their own solid supports. After the synthesis and purification of individual 
PNA and peptide sequences, they are finally conjugated to each other chemoselectively 
(68). Different methods can be discerned on the basis of the type of linkage between the 
peptide and PNA fragments. The functional linkages commonly used in fragment 
conjugation included amide, disulfide, thioether, oxime, and thioester etc. The general 
reactions used to prepare some of the linkages are summarized in Figure 5.  
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Figure 5. Schematic representation of the coupling strategies for PNA-peptide 
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a) Disulfide formation by thiopyridyl activation. b) Thioether formation. c) 
Thioether bond formation by maleimide functional group. d) Oxime formation. e) 
Native chemical ligation. 
 
A frequently used method is the linkage of fragments via a disulfide bond (70). The main 
reason is that disulfide bonds in PNA-peptide conjugates are vulnerable for cleavage in 
the reductive environment of the cytosol, thus releasing the free PNA sequence after 
intracellular uptake. For the formation of disulfide bond, both peptide and PNA 
fragments need to contain a thiol moiety, usually obtained by the incorporation of a 
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cysteine residue at either the C-terminal or N-terminal position. The preparation of 
disulfides originates from synthetic protocols developed in peptide chemistry and 
conducted following direct oxidation of two free thiols. This oxidative coupling method 
can give rise to the formation of symmetrical dimers, besides the desired product. The 
yield can be improved by the use of an excess of one of the fragments, which can give a 
more selective conversion. A more fruitful procedure to disulfide bond formation exploits 
the nucleophilicity of the thiol group of one of the fragments and activation of the other 
thiol group (71). An often-applied method to activate a thiol group towards nucleophilic 
substitution is its attachment to a thiopyridyl moiety. Nucleophilic substitution of this 
moiety by the incoming free thiol of the other fragment results in formation of the desired 
product. It is important to note that these coupling reactions should be carried out in an 
oxygen-free environment to prevent unwanted dimerization of molecules carrying a free 
thiol group.  
The nucleophilicity of the thiol group can also be applied to prepare PNA-peptide 
conjugates having more stable thioether linkages (72). For example, the thiol containing 
segment can react in a Michael type reaction with double bond of a maleimide functional 
group of the other fragment to give a covalently linked conjugate. Other potential 
nucleophiles, such as the side-chain amines in peptides are protonated at pH 8, rendering 
them unreactive.  
Chemoselective oxime formation is one of the most commonly used linkages in an 
alternative strategy to couple PNA and peptide fragments (73). This is because oxime 
formation is an efficient reaction, requires no harsh conditions, involves highly reactive 
functional groups, and introduction of the aldehydes and hydroxylamine on either 
fragment is relatively easy. In this strategy, a ketone functionality of one fragment was 
reacted with an amino-oxyacetic acid to the C-terminal side-chain amine functionality. 
The condensation was carried out in aqueous buffer at pH 4.2 and proceeds in a highly 
efficient manner.  
Recently, an alternative approach for the synthesis of peptide-PNA conjugates (74) was 
reported using Kent’s native chemical ligation strategy (75). This type of ligation is based 
on a reversible transthioesterification between two unprotected fragments, one containing 
a C-terminal thioester and the other an N-terminal cysteine. Rearrangement by a 
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proximity-driven nucleophilic attack of the cysteine amine on the thiolester irreversibly 
leads to an amide linkage and causes depletion of the freely equilibrating thioester 
intermediates and the formation of a single ligation product.  
In summary, the initial research motive of PNA-peptide conjugation was to improve the 
pharmacokinetic properties of therapeutically valuable PNA. Different types of peptides 
were used in the form of either noncovalent complexes or covalent conjugates to enhance 
the cellular uptake of PNA. The biological properties, for example, the antisense activity 
of similar conjugates, are shown to be influenced by the nature of the chemical linkage 
between the peptide and PNA fragments (76). The advance in both continuous solid-
phase synthesis and chemoselective conjugation methods opens the way to the design and 
synthesis of PNA-peptide hybrids possessing combined functionalities. These synthetic 
developments may eventually lead to the design of therapeutic probes based on PNA, 
which are able to target specific cell types, penetrate the cellular membrane, direct to the 
right cellular compartment, and fulfill a predetermined task, such as antisense /antigene 
activity, selective cleavage of DNA or RNA target sequences or activation of 
transcription.  
1.5 Aim of the project 
Many clinically valuable targets reside inside the cell membrane. As most of the Gd(III) 
based MR contrast agents are extracellular, therefore, developing efficient intracellular 
targeted MR contrast agent is required. The objective of the present project is to construct 
a series of targeted intracellular MR contrast agents aiming to image mRNA transcription 
by MRI. This thesis includes two major parts of work:  
The first part of this thesis takes an effort toward the design, synthesis, characterization, 
and in vitro testing of a series of CPP mediated intracellular MR contrast agents. Several 
typically applied CPPs would be selected as the transmembrane vectors to be conjugated 
with Gd(III) complexes as well as fluorescent dyes. Being labeled with fluorescent 
moiety, the dynamic transmembrane behavior, intracellular distribution and 
biocompatibility can be studied by fluorescence microscopy and spectroscopy in cells 
plated in 96well plates. In addition, after loading cells with MR contrast agents, the 
cellular relaxation rate and contrast enhancement data can be determined quantitively. 
Comparison studies on the relative efficacy, toxicity and uptake mechanism of individual 
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CPP, allowed for screening an optimal CPP for the intracellular delivery of MR contrast 
agents. 
Referred from the previous studies of Heckl (64) and Tian (62), there should be some 
kinetic differences between the antisense contrast agent and nonsense contrast agent 
when interacting with the target mRNA: the antisense contrast agents might have a longer 
retention time in the cells after binding with the target mRNA. The second part of this 
thesis is to design and synthesize antisense MR contrast agents, which conjugate PNA 
with cell penetrating peptides, Gd-DOTA and FITC. CPP will facilitate the intracellular 
delivery of the designed contrast agents. PNA fragment is the antisense to the targeting 
mRNA, which can specifically bind to complementary sequence in mRNA. With FITC 
and Gd-DOTA, fluorescent optical imaging as well as MR imaging can visualize the 
labeled cells. In vitro cell biological evaluations can be made on normal NIH/3T3 mouse 
fibroblasts to confirm the intracellular uptakes of the designed contrast agents and their 
biocompatibility using MR and fluorescent optical imaging techniques. The intracellular 
content of the antisense PNA contrast agents can be determined by MR or ICP-MS after 
the labeled cells were treated by concentrated HCl or nitric acid. The specificity of the 
antisense PNA contrast agents to the target sequence can be demonstrated by an in vitro 
hybridizing test. These preliminary studies on the antisense probes should support some 
helpful data for the further rational design and modification of intracellular targeted MR 
contrast agents. Further studies on transgenic cells which express target mRNA are 
needed to prove the specific accumulation of the antisense contrast agent by binding with 
the target mRNA. The long run goal of this research program is to track specific cells 
noninvasively by MR imaging using mRNA as the target.  
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Chapter 2. Synthesis and screening of cell penetrating peptides for the 
intracellular delivery of MR contrast agents 
2.1 Research design 
Aiming to screen an optimized vector for the intracellular delivery of MR contrast agents, 
five kinds of typically applied CPPs were selected: L-Tat49-57 (derived from HIV-1 Tat 
peptide) (77), D-Tat57-49 (retro-inverso isomer of Tat peptide), Orn-D-Tat57-49 
(substitution of Glutamine (q) residue with Ornithine (o) residue) (78), PTD-4 (a 
synthetic protein transduction domain) (79) and NLS (nuclear localization sequence of 
SV 40T-antigen) (80).  
Compared to the Boc/benzyl based scheme, Fmoc/tBu based solid phase peptide 
synthesis scheme has offered more flexibility for the modification of the peptide chain, 
more specificity in the cleavage of the Nα versus the side-chain protecting groups, and 
milder cleavage conditions. Therefore, Fmoc/tBu chemistry is selected in the peptide 
syntheses.  
One lysine residue is added at the N-terminal of every CPP as a linker. The Gd(III) 
chelate (DTPA or DOTA) is conjugated at the  α-NH2 group of Lys, whereas FITC is 
conjugated on the ε-NH2 group of Lys (Figure 6). Therefore, the designed MR contrast 
agents can label cells for optical as well as MR studies. The intracellular uptake 
efficiency of these contrast agents can be quantified with fluorescent spectroscopy and 
MR measurements; furthermore, the intracellular distribution of these probes could be 
demonstrated by fluorescent microscopy.   
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Figure 6. Schematic structures of Gd-DTPA and Gd-DOTA conjugated 
intracellular MR contrast agents 
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2.2. Results 
2.2.1 Synthesis and characterization of CPP conjugated MR contrast agents 
 Two different schemes were tried to synthesize the CPPs conjugates: fragment 
conjugation scheme and on-line continuous solid-phase synthesis scheme. 
 In the fragment conjugation scheme, we planned to prepare three fragments: Fmoc-
Lys(FITC)-OH, peptide, and DTPA dianhydride. First, CPP was synthesized by solid-
phase synthesis scheme on Wang resin using Fmoc/tBu protected amino residues. Fmoc-
Lys(FITC)-OH was synthesized by conjugating FITC with Fmoc-Lysine in solution. The 
resulting product Fmoc-Lys(FITC)-OH can be applied as a building block to be 
conjugated with CPPs. Afterwards, DTPA dianhydride coupled on the α-NH2 group of 
Lys to obtain the whole CPP conjugated ligand (Scheme-1). However, there is an 
unprotected phenol hydroxyl group in FITC. In the next steps of coupling Fmoc-
Lys(FITC)-OH with CPP or conjugate DTPA dianhydride with Lys, side products were 
formed which are derived from the carboxyl group coupling with the phenol group in 
FITC. Therefore, the yield of this scheme is very low. Further optimizations of this 
scheme were tried, such as protecting the phenol hydroxyl group in FITC. When the 
phenol hydroxyl group in FITC was protected with Trt, the over coupling side products 
was prevented. Therefore, the yield of the optimized scheme was much better than that of 
in unprotected scheme (For expamle, DTPA-Lys(FITC)-NLS-OH, the yield of 
unprotected scheme was 8%; the yield of protected scheme was 24%).  
In comparison, we have developed an on-line continuous solid-phase synthesis scheme: 
CPP was synthesized by solid-phase Fmoc/tBu-chemistry scheme on Wang resin using 
HATU or HBTU as the coupling reagents. After then Fmoc-Lys(Dde)-OH was applied as 
a linker. FITC was coupled on the ε-NH2 group of Lys on resin. Different bases, such as 
DIEA and triethylamine, were tested under different coupling condition. Finally, the 
optimal condition to couple FITC with Lys on resin is: 4eq FITC, 8eq DIEA for 7 hours 
(Scheme-2). The advantage of this scheme was that all coupling reactions were 
performed under mild conditions; and coupling FITC in the last step prevented the 
formation of side products, such as excess coupling on the phenol group of FITC. In 
addition, this continuous scheme allows the coupling process to be carried out by a fully 
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automated synthesizer. Therefore, the on-line continuous solid-phase synthesis scheme 
was selected as the optimal scheme for the synthesis of CPP conjugated contrast agents. 
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Scheme-2. Synthesis of CPP conjugated MR contrast agents by continuous 
solid-phase synthesis scheme 
 
In the on-line continuous solid-phase synthesis scheme, peptides were synthesized on 
Wang resin at the substitution about 0.50-0.60 mmol/g. Then, a Fmoc-Lys(Dde)-OH 
residue was applied as a spacer. Afterwards, Fmoc group was deprotected selectively, 
and DTPA or DOTA tris(tert-butyl) ester was coupled on the α-NH2 group of Lys. 
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Finally, the Dde group was removed by treatment with 2% hydrazine in DMF; FITC was 
coupled on the ε-NH2 group of Lys under the addition of DIEA. For every key 
intermediate, aliquots of the resin-bound conjugates were cleaved and side chain-
deprotected with H2O/TIS/TFA, and ESI-MS analysis was performed to confirm that the 
observed masses were consistent with the calculated molecular weights of the designed 
intermediates (e.g. Figure 7, Figure 8).  
 
 
 
 
 
 
 
Figure 7. ESI-MS Spectrum of the Tat peptide.  m/z = 670.5 ((M+2H)2+), 447.5 
((M+3H)3+), 335.9 ((M+4H)4+), and 268.9 ((M+5H)5+) were consistent with the 
calculated molecular weight (1339.6)  
 
 
 
 
 
 
 
Figure 8. ESI-MS Spectrum of DOTA-Lys(FITC)-D-Tat57-49-OH.  Detected 
molecular ions at m/z = 748.6 ((M+3H)3+), 561.9 ((M+4H)4+), 449.8 ((M+5H)5+), 
and 374.9 ((M+6H)6+) were consistent with the calculated mass of the desired 
product (2244.56) 
 
The conditions used to cleave the peptides from the resin simultaneously deprotected the 
tert-butyl esters on the DOTA ligands. After purified by RP-HPLC, the CPP conjugated 
ligands were characterized by ESI-MS (e.g. Figure 8). Then, CPP conjugates were all 
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successfully chelated with Gd3+ under mild conditions (for DTPA complex, 1eq of 
GdCl3.6H2O chelated at room temperature for 24h; whereas for DOTA complex, 1eq of 
GdCl3.6H2O chelated at 60˚C for 12 h). Final products were purified by HPLC and 
confirmed by ESI-MS (e.g. Figure 9, Table 1).   
 
 
 
 
 
 
 
Figure 9. ESI-MS Spectrum of Gd-DOTA-Lys(FITC)-L-Tat-OH. Detected 
molecular ions at m/z = 800.2((M+3H)3+), 600.2 ((M+4H)4+), 480.4 ((M+5H)5+), 
and 400.5 ((M+6H)6+) were consistent with the calculated molecular weight 
(2397.78). 
 
When the ESI-MS was measured at negative polarity, the spectrum of CPP conjugated 
Gd-DTPA complex showed ions at m/z = (M-1)1- and (M-2)2- (Figure 10). This spectrum 
is well consistent with the structure of CPP conjugated Gd-DTPA. There are two negative 
charged positions: one from the Gd-DTPA, another from the C-terminal of peptide. If the 
ESI-MS spectrum is amplified, the isotopes of Gd can be observed clearly (Figure 11). 
 
 
 
 
 
 
 
Figure 10. ESI-MS Spectrum of Gd-DTPA-Lys(FITC)-NLS-OH at negative 
polarity. Detected molecular ions at m/z = 1927.0 ((M-1)1-) and  963.8 (M-2)2- 
were consistent with the calculated molecular weight (1928.76). 
  
400.5 
480.4
600.2
800.2
+ 
0
2
4
6
8 
20
0
40
0
60
0
80
0
100
0
120
0
m/
z
963.8
 
1927.0 
(#10) 
0
2
4
6
6x1
200 400 600 800 1000 1200 1400 1600 1800 m/z
Chapter 2. Screening of CPP 
26  
 
 
 
 
 
 
 
Figure 11.  Isotopic pattern of Gd-DTPA-Lys(FITC)-NLS-OH 
 
Table 1. ESI-MS Data of CPP conjugated MR contrast agents 
 
Contrast agent Amino 
sequence 
HPLC 
purity (%) 
Molecular 
weight 
ESI-MS 
Gd-DTPA-L-Tat49-57 RKKRRQRRR 91 2385.71 796.6, 597.4, 
478.3, 398.9 
Gd-DTPA-D-Tat57-49 rrrqrrkkr 90 2385.71 796.3, 597.4, 
478.2, 398.8 
Gd-DTPA-PTD-4 YARAAARQ
ARA 
90 2250.44 1126.0, 750.9, 
563.5 
Gd-DTPA-NLS PKKKRKV 93 1928.76 964.4, 643.8, 
483.0 
Gd-DTPA-Orn-D-
Tat57-49 
rrrorrkkr 92 2371.72 791.7, 593.9, 
475.4, 396.4 
Gd-DOTA-L-Tat49-57 RKKRRQRRR 92 2397.78 800.2, 600.2, 
480.4, 400.5 
Gd-DOTA-D-Tat57-49 rrrqrrkkr 94 2397.78 800.3, 600.4, 
480.7, 400.6  
Gd-DOTA-Orn-D-
Tat57-49 
rrrorrkkr 96 2383.80 796.2, 596.5, 
477.7, 398.4 
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2.2.2 Determining the concentration and relaxivity of CPP conjugated contrast 
agents in aqueous solution 
The relative purities of CPP conjugated contrast agents were analyzed by HPLC, and the 
resulting purities of all contrast agents were higher than 90%. However, the exact purities 
of the contrast agents can not be determined by HPLC. Because the final products were 
purified by HPLC using 0.1%TFA in H2O/ACN as eluent, there is a high probability that 
TFA binds to positive charged amino residues as counter-anion. However, the exact 
nature and quantity of the counter-anion can not be determined by HPLC, thus, the real 
content of the contrast agent should be determined after they are dissolved in solvents. As 
every contrast agent molecule contains one FITC and one Gd chelate, the real 
concentration of these CPP conjugates could be determined by UV-Vis absorption at 
485nm of Fluorescein for the standard curve (ε=81000 cm2/mol) (Table 2). 
Determination of the concentration of CPP conjugates by UV-Vis absorption allowed for 
the calculation of the molar concentration without knowing the exact identity of the 
counter-anions. 
 
Table 2. Determining the concentration of CPP conjugated MR CAs in aqueous 
solution 
Contrast agent Calculated 
concentration (mM)
Measured 
concentration (mM) 
Purity (%) 
Gd-DTPA-L-Tat49-57 10 4.154 42 
Gd-DTPA-D-Tat57-49 10 4.101 41 
Gd-DTPA-PTD-4 10 2.560 26 
Gd-DTPA-NLS 10 5.312 53 
Gd-DTPA-Orn-D-Tat57-49 10 4.813 48 
Gd-DOTA-L-Tat49-57 10 4.069 41 
Gd-DOTA-D-Tat57-49 10 4.051 41 
Gd-DOTA-Orn-D-Tat57-49 10 4.141 41 
Calculated concentration was obtained by adding certain mg of CPP conjugates 
in aqueous solution; measured concentration was obtained by UV-Vis absorption. 
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Relaxivity measurements were acquired by taking the slope of a plot of the R1 relaxation 
rate versus concentration, where relaxivity (r1) is a measure of the ability of a contrast 
agent to shorten T1 (Table 3). MR measurements of the contrast agents in aqueous 
solution were performed at 3T at room temperature (~21°C). The results of MR 
measurement demonstrated that the relaxivity of CPP conjugated Gd(III) chelates are in 
the range of 6-9 mM-1 s-1, except Gd-DTPA-NLS (5.0 mM-1 s-1) and Gd-DOTA-D-Tat57-49 
(14.2 mM-1 s-1). 
 
Table 3. Relaxivity (r1) of CPP conjugated MR contrast agents 
 
Abbreviation Contrast agent Relaxivity (mM-1 s-1) 
CA1 Gd-DTPA-L-Tat49-57 8.8 
CA2 Gd-DTPA-D-Tat57-49 7.1 
CA3 Gd-DTPA-PTD-4 8.8 
CA4 Gd-DTPA-NLS 5.0 
CA5 Gd-DTPA-Orn-D-Tat57-49 6.3 
CA6 Gd-DOTA-L-Tat49-57 7.1 
CA7 Gd-DOTA-D-Tat57-49 14.2 
CA8 Gd-DOTA-Orn-D-Tat57-49 7.1 
 
MR measurements of the contrast agents in aqueous solution were performed at 
3T at room temperature (~21°C). 
 
2.2.3 In vitro studies of Gd-DTPA conjugates with L-Tat49-57, D-Tat57-49, PTD-4 and 
NLS  
At first, cell-penetrating peptides such as L-Tat49-57, D-Tat57-49, PTD-4 and NLS were 
selected to be conjugated with FITC and Gd-DTPA complexe respectively. The resulting 
contrast agents, Gd-DTPA-Lys(FITC)-L-Tat49-57 (CA1), Gd-DTPA-Lys(FITC)-D-Tat57-49 
(CA2), Gd-DTPA-Lys(FITC)-PTD-4 (CA3) and Gd-DTPA-Lys(FITC)-NLS (CA4) were  
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tested in vitro to study their intracellular delivery ability. These four CPPs were selected 
because HIV Tat peptide is one of the most studied and widely applied cell penetrating 
peptides; PTD-4 is one of the best artificially designed protein transduction domains 
according to the amphipathic model; NLS is one of the specific sequences that provide 
translocation into the nucleus. Although TAT, PTD-4 and NLS have been extensively 
employed for in vitro and in vivo delivery of different cargos into cells, little is known of 
the relative efficacy, toxicity and uptake mechanism of individual CPP, factors that will 
be critical in determining the optimal CPP sequence for intracellular MR contrast agent 
design.  
Cellular uptake of these compounds was confirmed by fluorescence microscopy and 
spectroscopy in NIH/3T3 mouse fibroblasts plated in 96well plates as well as by MR 
analyses in Eppendorf tubes (please see the cellular uptake assay in chapter 4). In brief, 
cells were treated with contrast agents at various concentrations in complete medium for 
18 hours. After cells were washed or extracellular fluorescence was quenched, 
internalized fluorescence was measured in a multiplate reader. Subsequently, 
fluorescence microscopy was performed with the same cells to observe the cellular 
localization.  
Toxicity via the reduction of the cell number was measured by counterstaining the cell 
nuclei with the DNA dye Hoechst 33342TM in the fluorescence reader. These values were 
also used to correlate the measured the measured CA fluorescence to the cell number per 
well. 
For MR imagings, exponentially growing fibroblasts were labeled with the contrast 
agents for 18 hrs. Cells were repeatedly HBSS washed, trypsinized and re-suspended in 
1.5 mL Eppendorf tubes at the rate of 1 x 107 cells in 500 µL complete DMEM. MRI of 
the cell pellets was conducted at 300 MHz on a vertical 7T/60 cm Bruker MRI Biospec 
system using T1-weighted spin-echo sequence at room temperature (~21°C). The axial 
slice of interest was positioned through the cell pellet.  
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Figure 12. Fluorescence microscopic images of NIH/3T3 cells after loading with 
contrast agents for 18 hours.  
A: 20 µM CA1; B: 20 µM CA2; C: 20 µM CA3; D: 20 µM CA4; bars represent 20 
µm  
 
Fluorescence microscopic images showed that all of these four contrast agents could be 
delivered efficiently into NIH/3T3 fibroblasts cells (Figure 12). This as well as 
spectroscopic data demonstrated that the uptake of CPP conjugates decreased in 
following order CA2 > CA1 > CA3 > CA4.  
However, examination of cellular toxicity showed following order CA3 > CA2 > CA1 > 
CA4. Overall, comparison of the uptake and toxicity suggests that D-Tat57-49 proves to be 
a useful cell-penetrating peptide for the development of new intracellular MR contrast 
agents. 
The results of T1- and T2-weighted MR measurements demonstrate that the uptake of 
agents CA1 and especially CA2 was sufficient to enhance significantly relaxation rates 
R1 and R2 in cells (Figure 13). Therefore, D-Tat57-49 peptide was confirmed as an efficient 
CPP for the intracellular delivery of MR contrast agents.  
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Figure 13. Changes in relaxation rates R1 and R2 in the cells after internalization 
of contrast agents.  
Values are means ± SEM, n=2-5; *p<0.05, **p<0.01, ***p<0.001, statistically 
significant different compared to control; a P<0.05 statistical significant 
difference. 
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2.2.4 In vitro comparison studies of Gd-DTPA and Gd-DOTA conjugates of L-Tat49-
57, D-Tat57-49, and Orn- D-Tat57-49 
Piwnica-Worms et al reported that intracellular uptake values increased up to 13-fold 
(78), when the chirality of the Tat peptide sequence was changed from L to D. 
Furthermore, length, sequence, and type of chelating domain all impacted peptide uptake 
into cells. They demonstrated that the highest level of uptake was found in Orn-D-Tat 
peptide by introduction of modifications in the sequence like replacement of glutamine 
(q) with ornithine (Orn, o). In addition, our preliminary studies demonstrate that Tat 
peptide especially D-Tat57-49 is very efficient to deliver Gd-DTPA complex into NIH/3T3 
cells. In order to study the relative intracellular uptake efficiency in detail, we planned to 
synthesize in parallel the Gd-DTPA complexes of L-Tat49-57 and its derivates, D-Tat57-49 
and Orn-D-Tat57-49.   
It was reported that DTPA-metal complexes had a lower thermodynamic stability 
compared to DOTA complexes if one of the N-acetate side chains was used for coupling 
via amide bond. Especially lower pH-values enhanced this effect. In addition, Aime’s 
group (32) reported that the lower stability of the Gd-DTPA-BMA complex was 
responsible for a shift in the dissociation equilibrium that resulted in the net transfer of 
Gd3+ ions on the cell membrane followed by a slower internalization process and 
accompanied by a drastic decrease in cell viability. On the other hand, Meade et al. (47) 
reported that NIH/3T3 transduction appears to be Gd(III) chelator dependent, preferring 
DTPA- to DOTA-based contrast agents. Therefore, Gd-DOTA conjugates with L-Tat, D-
Tat and D-Orn-Tat were synthesized and comparatively studied with corresponding Gd-
DTPA conjugate. 
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Figure 14. Microscopic images of NIH/3T3 cells incubated for 18 hrs with 20µM 
of Gd-DTPA-Lys(FITC)-L-Tat49-57 (a), Gd-DTPA-Lys(FITC)-D-Tat57-49 (b), Gd-
DTPA-Lys(FITC)-Orn-D-Tat57-49 (c), Gd-DOTA-Lys(FITC)-L-Tat49-57 (d), Gd-
DOTA-Lys(FITC)-D-Tat57-49 (e) and Gd-DOTA-Lys(FITC)-Orn-D-Tat57-49 (f).  
Bars represent 16 µm. Green: CA, Blue: H33342 (nuclei) 
 
d e f 
a b c 
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Figure 15. Fluorescence and toxicity of cells after incubation with 5 and 20 µM of 
various Tat conjugated CAs for 18 hrs. Values are means ± SEM (n=3). 
 
The results of fluorescent studies demonstrated that modifications of the native CPP 
sequence enhanced the uptake of the corresponding contrast agents. Thus, their 
intracellular delivery efficiency showed following order L-Tat ≤ D-Tat < D-Orn-Tat in 
both Gd-DTPA and Gd-DOTA complexes. However, the cellular toxicity showed the 
same order of L-Tat ≤ D-Tat < D-Orn-Tat (Figure 15).  
Interestingly, Gd-DTPA-CPP conjugates enter NIH/3T3 cells more efficiently than 
corresponding Gd-DOTA-CPP conjugates. These results could be a function of overall 
molecular charge or three-dimensional chelator conformations. The Gd-DTPA-D-Orn-
Tat shows the best intracellular delivery ability; however, it also expressed the highest 
cytotoxicity. When applied at 20 µM, Gd-DTPA-D-Orn-Tat showed a significant 
increased cellular toxicity (Figure 14, Figure 15). Therefore, comparison of the uptake 
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and toxicity suggests that D-Tat57-49 proves to be the optimal vector among the Tat 
peptide derivatives for the intracellular delivery of MR contrast agents. 
 
2.3. Discussion 
2.3.1 Synthesis of CPP conjugated, dual-labeled Gd(III)-based MR contrast agents 
2.3.1.1 Optimization of the coupling scheme for Fluorescein labeling  
At beginning, we tried to couple FITC with Fmoc-Lysine in solution. After purification 
by HPLC, the product Fmoc-Lys(FITC)-OH can be applied as a building block to be 
conjugated with CPPs. With several tests, we found there are some difficulties in this 
scheme: First, it is very difficult to obtain highly purified Fmoc-Lys(FITC)-OH 
compound at gram scale. Fmoc-Lys(FITC)-OH is very difficult to be re-crystallized in 
solutions, it has to be purified by RP-HPLC. But the solubility of this compound is very 
low in 0.1% TFA in water/ACN. Therefore, it is very difficult to obtain highly pure 
product in relative large scale. Second, there is an unprotected phenol hydroxyl group in 
FITC. When coupling Fmoc-Lys(FITC)-OH with CPP, side products were formed which 
are derived from the carboxyl group coupling with phenol group in FITC. Fischer et al. 
took great efforts to extend the applicability of carboxyfluorescein in solid-phase 
synthesis (81). They also found similar problems with coupling of the carboxyl group to 
the phenol group in carboxyfluorescein. In addition, they suggested that treatment of the 
resin with 20% piperidine in DMF could remove the over-coupling side products. 
However, this could not be confirmed in our systems. Referred from literature, we have 
developed and optimized the coupling scheme that enables us to label Lys on resin 
smoothly. Under eight times excess of DIEA, FITC couples completely with the ε-NH2 
group of Lys in 7 hours; and ESI-MS has demonstrated that there is no over-coupling 
side product formed.  
 
2.3.1.2 Conjugate DTPA dianhydride with peptides  
DTPA dianhydride is highly active, therefore, it can be coupled with free –NH2 group 
very fast. Unfortunately, there are two anhydride groups in every molecule of DTPA 
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dianhydride. Under normal coupling condition, there are a lot of side products formed, 
including double coupled product in which one DTPA coupled with two peptide 
sequences at both ends of DTPA, or hydrazine coupled on one end during the next Dde 
deprotect step with hydrazine, because hydrazine is highly nucleophilic reagent. To 
optimize the reaction condition, we tried to decrease the reaction speed in low 
temperature. The formation of side products was reduced dramatically when the reaction 
was controlled at 0-5 ˚C. And the coupling can be finished in 2~3 hours. Since we can 
not cool the temperature to 0-5 ˚C on the peptide synthesizer, this step can only be 
performed in a small glass flask. The second anhydride group was hydrolyzed (DMF: 
water: DIEA = 90:5:5) after DTPA dianhydride conjugated with peptide to prevent the 
formation of hydrazine coupled side product. The best scheme to avoid the double 
coupled side products is using tert-butyl protected DTPA (four of the five carboxyl 
groups in DTPA were protected by tert-butyl) as the building block (kindly provided by 
Prof. K.-H. Wiesmueller). With protected DTPA, the yield of the objective product is 
much higher than that with DTPA dianhydride.  
 
2.3.1.3 Formation of Gd-complexes  
Gd-DOTA-CPP complexes can be formed smoothly under the conditions of pH 6.5, 60˚C 
in 12h with 1eq GdCl3.6H2O. But there are many donor atoms on the peptide that might 
offer alternative coordination sites to the lanthanide ion. Initially, the complexes were 
dialyzed for 48 h after the CPP conjugated ligands were coordinated with gadolinium. 
But the resulting compounds showed very high r1 relaxivity (e.g.197.7 mM-1 s-1 for Gd-
DOTA-D-Tat; data not shown) in solution MR tests. We considered that possibly 
unspecifically bound Gd3+ (i.e. not chelated by DOTA-ligand) was still present in the 
preparation even after dialysis. The Gd-DOTA complexes are very stable even in an 
acidic environment. Thus, the unstable bound Gd(III) can be separated from Gd-DOTA-
CPP complexes by RP-HPLC with 0.1%TFA in H2O/ACN.  
However, the coordinating condition and stability of Gd-DTPA-CPP complexes are 
different from that of Gd-DOTA complexes. Gd3+ could be chelated with DTPA-CPP 
ligand at room temperature. But Gd-DTPA-CPP complexes are not as stable as Gd-
DOTA-CPP complexes, because one carboxyl group of DTPA was used for coupling to 
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the peptide. Thus, if purified by RP-HPLC with 0.1%TFA in H2O/CAN, some of Gd was 
released from DTPA. We have tried to dialyze the chelating mixture to remove free Gd3+. 
However, even after 72h, there was still free Gd3+ observed with xylenol orange 
indicator. Finally, we purified Gd-DTPA-CPPs by RP-HPLC with 0.05%TFA in 
H2O/ACN. The ESI-MS confirmed that Gd3+ is still chelated with DTPA, and the MR 
measurement demonstrated the unspecific bound Gd(III) was removed.  
 
2.3.1.4 Relaxivity of CPP conjugated MR contrast agents 
The r1 relaxivity of CPP conjugated Gd(III) chelates are in the range of 6-9 mM-1 s-1 at 3 
T, except Gd-DTPA-NLS (5.0 mM-1 s-1) and Gd-DOTA-D-Tat57-49 (14.2 mM-1 s-1). These 
results are in accordance with published literature for monomeric chelates. Meade et al 
reported the r1 relaxivity of Gd-DTPA-(Arg)8 is 6.8 mM-1 s-1 at 3T (46); and Piwnica-
Worms et al reported the r1 relaxivity of Gd-DOTA-D-Tat is 7.94 mM-1 s-1 at 4.7T (82). 
In addition, Ranganathan et al. (83) have shown that the relaxivity per Gd(III) correlates 
well with molecular weight for a series monomeric and multimeric Gd(III) chelates. They 
demonstrated that increases in relaxivity correlate approximately with increasing 
molecular weight for spherical molecules. For example, when the molecular weight of 
Gd(III) complexes are in the range of 2,200 to 2,400, their r1 relaxivities at 20MHz are in 
the range of 8.4 to 8.8 mM-1 s-1 per Gd(III). Indeed, most of our CPP conjugated Gd(III) 
complexes have their molecular weight in the range of 2,200 to 2,400; and their r1 
relaxivity are in the range in of 6-8.8 mM-1 s-1. The r1 relaxivity NLS conjugated Gd-
DTPA is 5.0 mM-1 s-1; this is correlate with its molecular weight (1929). These results 
demonstrated that the r1 relaxivity of these CPP conjugated Gd(III) complexes are 
reliable considering their molecular weight. However, the r1 relaxivity of Gd-DOTA-D-
Tat57-49 (14.2 mM-1 s-1) is exceptionally high. We have synthesized and measured four 
batches of Gd-DOTA-D-Tat57-49. The r1 relaxivity values were still in the range of 13~14 
mM-1 s-1. The reason of this exceptional value is still under investigation.  
There are some differences in the value of relaxivity from batch to batch of the same CPP 
conjugated Gd(III) chelates. This might be because TFA bind with positive charged 
amino residue as the counter-anions and the real concentration of these MR contrast 
agent were determine by the UV-Vis absorption of FITC. Relaxivity measurements were 
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acquired by taking the slope of a plot of R1 versus concentration. Although every 
molecule of the CPP conjugated ligand includes only one FITC and one ligand group, the 
content of Gd(III) might different from batch to batch. There is still the possibility that 
some of the ligands have not completely chelated with Gd(III), or that free Gd(III) still 
remaining unspecifically in the CPP, considering many donor atoms on the peptide which 
might offer alternative coordination sites to the lanthanide ion. Therefore, other methods 
which can determine Gd(III) directly (such as ICP-MS) would be better to quantify the 
Gd(III) content in the ligands. And the resulting relaxivity would be more reliable than 
our current method. (Determination of Gd(III) by ICP-MS is under progress by the 
collaboration group at the University of Bremen) 
2.3.2 Intracellular delivery of CPP conjugated MR contrast agents 
Efficient delivery of diagnostic compounds to the cell interior using CPPs has enabled 
novel applications in molecular imaging. Peptide-based imaging agents in particular are 
desired for molecular imaging applications because of their potential for specific 
detection of a target, great flexibility in design, facile synthesis, and the availability of 
well-characterized chelation cores for incorporation of imaginable metals, such as 
technetium (99mTc) (44) for nuclear imaging and gadolinium (Gd) for MRI (47).  
We have synthesized a series of Gd-DTPA or Gd-DOTA complexes, which were 
conjugated with L-Tat49-57, D-Tat57-49, Orn-D-Tat57-49, PTD-4 and NLS, respectively, and 
tested their intracellular delivery in vitro. The biological evaluation showed some 
advisable results about their relative efficacy, toxicity and possible uptake mechanism, 
which will be critical in determining the optimal CPP sequence for intracellular MR 
contrast agent design.  
 Both the MR and the fluorescence results from our biological studies confirmed that Tat 
peptide and its derivatives are efficient in the intracellular delivery of MR contrast agents.  
HIV Tat peptide is the most intensively studied and widely applied cell penetrating 
peptides. An endocytic uptake had already been demonstrated for the entire HIV-1 Tat 
protein in 1991.  However, the precise intracellular uptake mechanism of Tat peptide still 
appears controversial and requires further investigations. Contradictory results are often 
obtained. They could result from experimental variations in, for example, the diversity of 
the Tat peptide sequence used to promote the translocation activity, the wide variety of 
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cell lines studied, the differing protocols applied to investigate the entry mechanism or 
the high diversity of cargoes, all of which might influence the behavior of Tat peptide 
during the cellular entry process (78). In the case of delivering MR contrast agents, 
Meade et al. (47) reported that the variables of Gd (III) chelator (DOTA or DTPA) and 
cell type (NIH/3T3, RAW264.7, or MDCK) could be attributed to the variable uptake of 
MR contrast agents. NIH/3T3 and RAW264.7 transduction appears to be Gd(III) chelator 
dependent, preferring DTPA- to DOTA-based contrast agents. This result is demonstrated 
in our cell biological studies also: Gd(III)-DTPA complexes were more efficient to enter 
NIH/3T3 cells than Gd(III)-DOTA complexes. However, the cytotoxicity of Gd(III)-
DTPA complexes were also higher than that of Gd(III)-DOTA complexes. These results 
could be a function of overall molecular charge or three- dimensional chelator 
conformations.  
Our comparison studies of the uptake and toxicity on NIH/3T3 cells suggest that D-Tat57-
49 contrast agent could label cells sufficient to enhance significantly relaxation rates R1 
and R2 for MR measurements, and without effecting cell bioavailability when 
concentration less than 20µM were applied. Therefore, D-Tat57-49 peptide proves to be a 
useful cell-penetrating peptide for the further development of new intracellular MR 
contrast agents. 
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2.4. Summary  
1). Two synthesis schemes were developed in comparison to synthesize the CPPs 
conjugated MR contrast agents: fragment conjugation scheme and on-line continuous 
solid-phase synthesis scheme. The continuous solid-phase synthesis scheme was proved 
to be optimal compared to fragment conjugation scheme in the synthesis of CPP 
conjugates. 
2). Eight intracellular MR contrast agents, which are  Gd-DTPA-Lys(FITC)-L-Tat49-57-
OH, Gd-DTPA-Lys(FITC)-D-Tat57-49-OH, Gd-DTPA-Lys(FITC)-Orn-D-Tat57-49-OH, 
Gd-DTPA-Lys(FITC)-NLS-OH, Gd-DTPA-Lys(FITC)-PTD-4-OH, Gd-DOTA-Lys 
(FITC)-L-Tat49-57-OH, Gd-DOTA-Lys(FITC)-D-Tat57-49-OH and Gd-DOTA-Lys(FITC)-
Orn-D-Tat57-49-OH, were synthesized by continuous solid phase synthesis scheme. The 
key intermediates and final products were characterized by ESI-MS. The detected 
molecular ions were consistent with the calculated molecular weight. The r1 relaxivity of 
these contrast agents in aqueous solution are in the range of 6-9 mM-1 s-1 at 3 T, except 
Gd-DTPA-NLS (5.0 mM-1 s-1) and Gd-DOTA-D-Tat57-49 (14.2 mM-1 s-1).  
3). Fluorescence microscopy imaging as well as spectroscopy data in NIH/3T3 cells 
plated in 96well plates demonstrated that the delivery efficiency showed following order 
Orn-D-Tat > D-Tat > L-Tat > PTD-4 > NLS.  
4). Both the MR and the fluorescence results confirmed that the Tat peptide and its 
derivatives are efficient in the intracellular delivery of MR contrast agents. Our studies on 
uptake and toxicity in NIH/3T3 cells suggest that D-Tat57-49 contrast agent could label 
cells sufficiently to enhance significantly relaxation rates R1 and R2 in MR measurements, 
thus D-Tat57-49 peptide proves to be a useful vector for the development of novel 
intracellular MR contrast agents. 
5). The design of a reliable intracellular delivery system offers a powerful tool to label 
cells with MR contrast agents. The properties of the Gd(III) complexes described in this 
chapter are well suited for facilitating the study of biological activity in vivo by MRI  
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Chapter 3: Design, synthesis and in vitro evaluation of antisense PNA 
conjugated intracellular MR contrast agents 
3.1 Research design  
To be useful as a probe, an antisense PNA must target an unique mRNA sequence in the 
objective cells. The targeted mRNA should be highly abundant in cells to ensure good 
detection sensitivity and selectivity for MR imaging. Therefore, as a proof of principle 
we chose the mRNA of the red fluorescent dsRed protein as target. The gene for this 
protein, originating from a coral of the Discosoma genus, is widely used as a transfection 
marker in model systems, such as yeast, E. coli, C.elegans, and zebrafish. Furthermore, 
Nagy et al. (84) developed a system which expresses dsRed protein in mouse embryonic 
stem cells, embryos and adult animals (Figure 16). Thus, this model system can be 
applied in future for in vitro and in vivo studies.  
 
                                       
Figure 16. Red fluorescent protein expression in mouse embryos and adult 
animals (Vintersten et al., Genesis. 2004; 40(4): 241-6) 
 
The CPP and PNA fragments will be synthesized by solid phase by the Fmoc mediated 
scheme. Synthetically, PNAs incorporate repetitive elements, which are readily amenable 
to assemble via automated solid phase synthesizer. Specifically, protecting group 
strategies, solid phase peptide synthesis protocols, de-protection methods and purification 
procedures developed for peptide synthesis are adapted to the synthesis of PNAs. 
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Furthermore, the use of Fmoc protection offers several advantages, including milder 
synthesis conditions, improved monomer solubility, high coupling efficiencies and 
facilitated purification of the final product.       
 
 
Figure 17. Schematic structure of targeted intracellular CA 
 
This chapter aims to design and synthesize intracellular MR contrast agents, which 
conjugate PNA with cell penetrating peptides, Gd-DOTA and FITC (Figure 17). The 
designed antisense contrast agent will include three functional domains: first, CPP helps 
intracellular delivery of the contrast agent; second, PNA fragment is the antisense to the 
mRNA of dsRed, which specifically bind with complementary sequence in mRNA of 
dsRed; third, Gd-DOTA and FITC forms reporter domain for fluorescent optical imaging 
as well as MR imaging.  
 In vitro cell biological evaluations were made on normal NIH/3T3 mouse fibroblasts and 
a transgenic cell line to test the internalization of these compounds into cells, their 
biocompatibility and specificity using MR and fluorescent optical imaging techniques. 
Furthermore, the intracellular content of the antisense PNA contrast agents was 
determined by MR after the labeled cells were treated by concentrated acid. The 
specificity of the antisense PNA contrast agents to the target sequence was demonstrated 
by an in vitro hybridizing-ELISA test. These preliminary studies on the antisense probes, 
designed for imaging mRNA transcription by MRI, support some helpful data for the 
further rational design and modification of intracellular targeted MR contrast agents. 
vector
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3.2 Results  
3.2.1 Design of antisense PNA-CPP conjugates 
In chapter one, we demonstrated that conjugates of Gd-DTPA or Gd-DOTA with cationic 
CPP, such as Tat peptide and its derivatives, could be internalized into cells in sufficient 
quantities to enhance contrast in MR images. Cell biological tests demonstrated that the 
modified CPP D-Tat57-49: (retro-inverso sequence with D-amino acids); improved 
intracellular delivery with acceptable biocompatibility when compared to natural CPP. 
Therefore, we selected D-Tat57-49 as a vehicle for the intracellular delivery of the PNA 
conjugates in the current study.  
Recently, it was shown that DTPA-metal complexes had a lower thermodynamic stability 
compared to DOTA complexes if one of the N-acetate side chains is used for coupling 
via amide bond (85). Especially lower pH-values enhanced this effect. In addition, 
Aime’s (32) group reported that the lower stability of the Gd-DTPA-BMA complex was 
responsible for a shift in the dissociation equilibrium that resulted in the net transfer of 
Gd3+ ions on the cell membrane followed by a slower internalization process and 
accompanied by a drastic decrease in cell viability. Therefore, Gd-DOTA was selected as 
the MR contrast agent. 
Two PNA conjugates were designed after a BLAST (Basic Local Alignment and Search 
Tool) database search: The sequence of anti-dsRed PNA is tcc gtg aac ggc 
(corresponding to base 61 to 72 of dsRed cDNA sequence) marked red in Figure 18, 
which specifically targets to the mRNA of dsRed. This sequence of 12 bases is unique for 
dsRed and has no significantly similar sequence in mouse genome. While the nonsense 
PNA (gtt cag agt cta) does not correspond to any known mammalian gene or sequence of 
the dsRed gene (Figure 19).  
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atggcctcct ccgaggacgt catcaaggag ttcatgcgct tcaaggtgcg 
catggagggc tccgtgaacg gccacgagtt cgagatcgag ggcgagggcg 
agggccgccc ctacgagggc acccagaccg ccaagctgaa ggtgaccaag 
ggcggccccc tgcccttcgc ctgggacatc ctgtcccccc agttccagta 
cggctccaag gtgtacgtga agcaccccgc cgacatcccc gactacaaga 
agctgtcctt ccccgagggc ttcaagtggg agcgcgtgat gaacttcgag 
gacggcggcg tggtgaccgt gacccaggac tcctccctgc aggacggctc 
cttcatctac aaggtgaagt tcatcggcgt gaacttcccc tccgacggcc 
ccgtaatgca gaagaagact atgggctggg aggcctccac cgagcgcctg 
tacccccgcg acggcgtgct gaagggcgag atccacaagg ccctgaagct 
gaaggacggc ggccactacc tggtggagtt caagtccatc tacatggcca 
agaagcccgt gcagctgccc ggctactact acgtggactc caagctggac 
atcacctccc acaacgagga ctacaccatc gtggagcagt acgagcgcgc 
cgagggccgc caccacctgt tcctg 
Figure 18. cDNA sequence of dsRed and the selected fragment (red) for the 
antisense MR contrast agent. The red marked sequence is specific for dsRed 
and is selected to design the PNA sequence antisenses to mRNA of dsRed. 
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Figure 19. Schematic structure of antisense dsRed mRNA targeting contrast 
agent (dsRed CA) and nonsense contrast agent (nonsense CA) 
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Scheme 3. Synthesis of PNA conjugated MR contrast agent. 
Reagents and conditions: (i) Fmoc-AEEA-OH, HATU, DIEA, DMF; (ii) Fmoc/Bhoc 
protected monomers, HATU, DIEA, DMF; (iii) Fmoc-Lys(Dde)-OH, HATU, DIEA, 
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DMF; (iv) DOTA-(tBu)3-OH, HATU, DIEA, DMF, 2 h; (v) FITC, DIEA, DMF, 7 h; 
(vi) TFA: m-Cresol: TIS: H2O (90:5:2.5:2.5), 4 h; (vii) GdCl3.6H2O, 60˚C, 12 h;  
 
3.2.2 Synthesis of Gd-DOTA-Lys(FITC)-PNA-CPP conjugates 
The conjugates were synthesized by a continuous solid phase synthesis scheme using 
Fmoc/Bhoc chemistry for PNA synthesis (Scheme 3). First, D-Tat57-49 was synthesized 
on Wang resin at a low level of substitution (0.30 mmol/g) like described in charpter 2. 
Then, PNA building blocks were coupled continuously through an AEEA spacer. A 
Fmoc-Lys(Dde)-OH residue was applied as second spacer. Afterwards, Fmoc group was 
deprotected selectively; and DOTA tris(tert-butyl) ester was coupled on the α-NH2 group 
of Lys. Finally, the Dde group was removed by treatment with 2% hydrazine in DMF and 
FITC was coupled on the ε-NH2 group of Lys under the addition of DIEA (8eq).  
The advantage of this scheme was that all coupling reactions were performed under mild 
conditions preventing the formation of side products, such as excess coupling on the 
phenol group of FITC. Because of this continuous scheme, the whole coupling process 
can also be carried out by a fully automated synthesizer. 
After purified by semi-preparative reversed-phase HPLC, the products were characterized 
by ESI-MS: for anti-dsRed PNA conjugate, detected molecular ions at m/z = 1126.3 
((M+5H)5+), 938.9 ((M+6H)6+), 805.0 ((M+7H)7+), and 704.3 ((M+8H)8+) were 
consistent with the calculated mass of the desired product (5628.2) (e.g. Figure 20). For 
nonsense PNA conjugate, detected molecular ions at m/z = 1129.1 ((M+5H)5+), 941.1 
((M+6H)6+), 806.9((M+7H)7+), and 706.1 ((M+8H)8+) were consistent with the calculated 
mass of the desired product (5642.4).  
 
 
 
 
 
 
 
Figure 20. ESI-MS Spectrum of anti-dsRed PNA ligand 
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3.2.3 Chelating with gadolinium and purification 
PNA conjugates were successfully chelated with Gd3+ under mild conditions (at 60˚C for 
12 h). After chelating with gadolinium, the complexes were characterized by ESI-MS: 
From anti-dsRed PNA complex, detected molecular ions at m/z = 964.7 ((M+6H)6+), 
826.9 ((M+7H)7+), 723.8 ((M+8H)8+), and 643.1 ((M+9H)9+) were consistent with the 
calculated mass of the desired product (5782.4) (in the following called dsRed CA) (e.g. 
Figure 21). For nonsense PNA complex, detected molecular ions at m/z = 1159.7 
((M+5H)5+), 966.7 ((M+6H)6+), 829.1((M+7H)7+), and 725.7 ((M+8H)8+) were consistent 
with the calculated mass of the desired product (5796.6; nonsense CA). These mass 
spectra demonstrated that the PNA conjugates successfully chelated with gadolinium.  
 
 
 
 
 
 
 
Figure 21. ESI-MS spectrum of anti-dsRed contrast agent 
 
Before biological testing, the compounds were purified carefully to separate free 
gadolinium and other inorganic salts. Initially, the chelating mixtures were dialyzed for 
48 h. But the compounds still showed very high R1 and especially R2 relaxation rates in 
cell MR tests (210 and 813 % of control for 1 µM, respectively; data not shown). We 
ascribed this to the possibility that some Gd3+ not chelated by DOTA-ligand but weakly 
bound to other potential chelating moieties (amide in peptide and PNA backbone, amino 
groups in the nucleobases, etc) in the peptide/PNA complex was still present in the 
preparation even after dialysis. Thus, we modified the purification process. The chelating 
mixtures were purified first by HPLC to separate the unstable bound Gd3+, and 
subsequently, the compounds were dialysed to remove other impurities. After this 
purification the observed relaxivities of both CA in water were between 3.4 and 5.3 (mM-
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1sec-1). These values are in the expected range for compounds with one DOTA-
complexed gadolinium (10). The relaxivity was not further decreasing in a competitive 
assay with free DTPA indicating the complete removal of unspecifically bound Gd3+ 
during the additional purification steps. 
3.2.4 Determining the concentration and relaxivity of PNA conjugated contrast 
agents  
Because the final products were purified by HPLC using 0.1%TFA in H2O/ACN as 
eluent, there is as well a high probability for the PNA conjugated contrast agents that 
TFA interacts with positive charged amino residues as the counter-anions. Thus, the real 
concentrations of CPP conjugates were determined by UV-Vis absorption of the 
fluorescence mioety.  
 
Table 4. Determination of the concentration of PNA conjugated MR CAs 
Contrast agent Calculated 
concentration (mM) 
Measured 
concentration (mM) 
Purity (%) 
dsRed CA 5 2.941 59 
Nonsense CA 5 3.383 67 
 
Relaxivity measurements were acquired by taking the slope of a plot of R1 versus the 
determined concentration. Relaxivity measurements of contrast agents were performed in 
the concentration range of 0 – 30 µM at 300 MHz at room temperature (~21˚C). Contrast 
agents were diluted in water and 1ml aliquots were transferred to Eppendorf cups. The 
observed relaxivities of dsRed contrast agent and nonsense contrast agent in water were 
3.3 and 5.3 (mM-1sec-1), respectively. These values are in the expected range for 
compounds with one DOTA-complexed gadolinium.  
 
Table 5. Relaxivity of PNA conjugated contrast agents 
Contrast agent PNA sequence Relaxivity (mM-1 s-1) 
dsRed CA tcc gtg aac ggc 3.4 
Nonsense CA gtt cag agt cta 5.3 
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3.2.5 In vitro fluorescence studies on NIH/3T3 embryonic mouse fibroblasts 
To determine whether these synthesized PNA-peptide conjugates are internalized into 
cells and to evaluate the distribution of the compounds in subcellular compartments, 
fluorescence spectroscopy and fluorescence microscopic studies were performed with 
both contrast agents at first on NIH/3T3 embryonic mouse fibroblasts. The NIH/3T3 cells 
are not containing any target molecule for both PNA conjugated contrast agents.  
The results of fluorescence spectroscopy (Figure 22) showed that both contrast agents 
could enter efficiently into 3T3 cells in a concentration dependent manner from 0.5 µM to 
9.0 µM. At concentrations higher than 5.0 µM, the cytotoxicity of these compounds 
increased dramatically (data not shown). No significant differences between the two 
compounds were observable, as expected for a cell line without any target mRNA. 
Therefore, further results were shown solely of the dsRed CA and at concentrations 
below 5.0 µM. 
 
 
Figure 22. Cell internalization of dsRed and nonsense CA into 3T3 cells 
measured by fluorescence spectroscopy. Cells were incubated with contrast 
agents at various concentrations in complete medium for 18 h. External 
fluorescence was quenched with trypan blue and subsequent washes with 
HBSS; Values are means ± SEM, n=3-10 with six replicates each. 
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Figure 23. Fluorescence microscopic images displaying the cellular localization 
of dsRed CA in 3T3 cells  
Cells were incubated with dsRed CA at 5 µM in complete medium for 18 h, cell 
nuclei were counterstained by Hoechst 33342 and external fluorescence was 
quenched with trypan blue and subsequent washes with HBSS. 
dsRed CA: green (FITC fluorescence); nuclei: blue (Hoechst 33342); bar 
represents 20 µm. 
 
Fluorescence microscopy imaging (Figure 23) demonstrated that the dsRed CA (green) 
could enter cells and was located predominatly in vesicles around the nucleus (blue) 
whereas no uptake into the nucleus was observed. The vesicular distribution indicates a 
predominantly endosomal uptake mechanism of dsRed CA. We observed only few cells 
with low cytosolic fluorescence at higher concentrations might be indicating a slow 
release from these endocytic vesicles in our model system.  
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Figure 24. CA fluorescence (left Y-axis) and cell number (right Y-axis) in 3T3 
cells after incubation with 5 µM of Gd-DOTA-Lys(FITC)-D-Tat57-49 and Gd-DOTA-
Lys(FITC)-PNA-D-Tat57-49 for 18 hrs. Values are means ± SEM (n=3). 
 
The intracellular uptake of Gd-DOTA-Lys(FITC)-PNA-D-Tat57-49, Gd-DOTA-
Lys(FITC)-D-Tat57-49 and Gd-DOTA-Lys(FITC)-PNA were compared to visualize the 
influence of the contrast agent structure on the internalization. Whereas Gd-DOTA-
Lys(FITC)-PNA without CPP was very poorly internalized (data not shown), Gd-DOTA-
Lys(FITC)-D-Tat57-49 showed efficient intracellular uptake at concentration of 20-30µM 
(see chapter 2). However, Gd-DOTA-Lys(FITC)-PNA-D-Tat57-49 could label cells very 
efficiently allowed at concentrations as low as 0.5-5 µM. Figure 24 shows the comparison 
of the fluorescence spectroscopic results for the incubation of 3T3 cells with 5 µM of Gd-
DOTA-Lys(FITC)-D-Tat57-49 and Gd-DOTA-Lys(FITC)-PNA-D-Tat57-49, respectively. 
The PNA-CPP conjugate showed much better internalization compared to the only CPP 
coupled contrast agent, but accompanied by an increased cytotoxicity indicated by the 
reduced cell number. These results suggest that there should be a synergistic effect 
between CPP and PNA sequence. Gd-DOTA-Lys(FITC)-PNA-D-Tat57-49 is the best 
intracellular MR contrast agent in all our synthesized probes until now. 
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3.2.6 In vitro MR studies on NIH/3T3 embryonic mouse fibroblasts 
Cellular uptake of the PNA conjugated contrast agents was also confirmed by in vitro 
MR studies at 300 MHz. After loading with dsRed CA, the relaxation rate R1,cell inside 
3T3 cells (Figure 25) increased linearly with the applied (extracellular) labeling 
concentration of contrast agent (from 0.1 µM to 1.0 µM). Up to now, we are still 
developing a method to quantify the exact concentration of gadolinium inside the cells 
after the labeling period of 18 h. Thus, in a first approach the apparent “intracellular” 
relaxation rates are plotted against the extracellularly applied concentration. 
Nevertheless, the measured intracellular relaxation rate increased significantly after 
loading with 0.5 µM and 1 µM dsRed contrast agent. Contrast enhancement in T1-
weighted MR images of cells was also observable at these low concentrations, 
exemplarily is shown for a single experiment in Figure 26. The results of the MR 
measurements are summarized in Table 6, also illustrating that already at 0.5 µM applied 
concentration, a statistically significant increase of the intracellular relaxation rate R1,cell 
and thus a contrast enhancement was detectable. No significant effect on T2 was 
observable at these low concentrations (data not show). 
 
 
Figure 25. Relaxation rate R1,cell in 3T3 cells after loading with dsRed CA. After 
treated with dsRed CA for 18 h, cells were trypsinized, centrifuged and re-
suspended in 1.5 mL Eppendorf tubes at 1 x 107 cells/500 µL in complete DMEM 
for MR studies. The measured relaxation rates were plotted vs. the extracellularly 
applied labeling concentration. Control: cells incubated with culture medium 
without CA. 
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Figure 26. T1 weighted MR images of 3T3 cells after loading with dsRed CA for 
18 h. Sagittal images were obtained with a field of view 14 x 6.9 cm2, matrix 256 
x 256, slice thickness 2 mm, SW 100 kHz, TE 9.2 ms, TR 1500 ms, 26 averages 
for T1 weighted images. Control: cells incubated with culture medium without CA. 
 
 
Table 6. Intracellular relaxation rates R1,cell in 3T3 cells after loading with dsRed 
CA for 18 h. 
Labeling concentration [µM] 0.5 1.0 2.5 
R1,cell [% of control] 112 ± 0.5** 132 ± 3.7** 144 ± 1.9** 
n 3 3 2 
 
Values are means ± SEM; **: p<0.01 statistically different as compared to control 
(100 ± 0.6 %), ANOVA with Dunnett´s post test; n: number of experiments, each 
with two replicates.  
 
3.2.7 Determination of intracellular Gd3+ content  
In order to determine the real intracellular relaxivity of the antisense PNA contrast agent, 
the content of probe should be measured via Gd(III). According to the literature (32), the 
intracellular Gd3+ content can be determined by a MR method: After incubated with MR 
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contrast agent, the cells were recovered enzymatically with trypsin/EDTA mixture as was 
usually done for cell detachment. Then the collected cells were treated with 6M HCl at 
120˚C overnight. Upon this treatment, all Gd can be solubilized as free aquo-ion. By 
measuring the relaxation rates of these solutions by MR and in comparison to a standard 
curve, it is possible to determine its concentration.  
At first, we made the parallel standard curves with or without cells: For preparing the 
standard curve in solution without cells, different concentrations of GdCl3 diluted in 6M 
HCl and heated at 120˚C overnight (Figure 27). For preparing the standard curve in 
solution with cells, different concentrations of GdCl3 were mixed with 107 cells and 
treated with 12M HCl (V/V=1:1, the final concentration of HCl is 6M) at 120˚C 
overnight. Afterwards, the relaxation rate were measured by MR. The resulting standard 
curves were made by plotting R1 versus concentration (Figure 28).  
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Figure 27. Gd(III) relaxation standard curve in 6M HCl.  
Different concentrations of GdCl3 in 6M HCl were prepared and heated at 120˚C 
overnight. MR measurement was performed at 300MHz. 
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Figure 28. Gd(III) relaxation standard curve with cell background (6M HCl in 
medium). Different concentrations of GdCl3 in the mixture of 107 cells were 
prepared and heated at 120˚C overnight. MR measurement was performed at 
300MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Gd(III) relaxation standard curve at low concentration (0.5µM-50µM) 
with cell background (6M HCl in medium). Different concentrations of GdCl3 in 
the mixture of 107 cells with 6M HCl were prepared and heated at 120˚C 
overnight. MR measurement was performed at 300MHz. 
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Comparing the standard curves, there is a significant difference between the relaxation 
value of Gd(III) in water or in cell medium. Especially at low concentrations of 0.5 µM-5 
µM (Figure 29), the relaxivity for low Gd(III) concentrations in cell lysates (33.7 mM-1 s-
1) is almost three times higher than that of Gd(III) in aqueous 6M HCl (11.2 mM-1 s-1).  
The relaxation rates for the labeled cells were located in this low range. If the 
intracellular content of Gd(III) was calculated according the relaxivity of Gd(III) in 6M 
HCl, the resulting value were unreasonably high.  
Thus, the intracellular content of Gd(III) should be calculated according to the relaxivity 
of Gd(III) in cell lysates. The resulting intracellular Gd(III) contents were in the range of 
10-9~10-8 mol Gd/107 cells, which is in agreement with the values from literature (82). 
The volume of 3T3 fibroblasts can be estimated by a centrifuge measurement in special 
tubes. The resulting volume of 1 x 107 NIH/3T3 mouse fibroblasts was estimated to 
approx 28 µl. Thus, we can determine the real intracellular relaxivity of dsRed CA by 
taking the slope of a plot of R1 versus intracellular contrast agent concentration. The 
resulting intracellular relaxivity of dsRed CA is 2.5 ± 0.3 mM-1 s-1 (Figure 30).  
 
 
 
Figure 30. Determination of intracellular relaxivity of dsRed CA by MR 
measurements of cell lysates and Gd standards. (Estimated volume of 1 x 107 
3T3 fibroblasts: 28±2 µl). Dashed lines show the 95% confidence interval.  
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3.2.8 In vitro test of antisense PNA hybridizing with target sequence 
An in vitro binding assay was performed to demonstrate the antisense specificity of 
dsRed contrast agent according to a protocol supported by Corning Costar Company. A 
target oligodeoxynucleotide sequence was immobilized in DNA-BINDTM 96-well plates. 
Then dsRed CA and nonsense CA were hybridized with the immobilized oligo-DNA 
sequence (Figure 31). The amount of hybridized contrast agent was determined by an 
ELISA assay, which can quantify the concentration of FITC by an antibody (86).  This in 
vitro PNA-DNA binding assay confirmed that there is a significant higher specificity of 
the antisense dsRed CA in comparison to its nonsense counterpart (Figure 32). However, 
there are several positively charged amino acid residues in the D-Tat peptide which was 
conjugated to the PNA fragment. These positively charged amino acid residues can bind 
with the negatively charged backbone of DNA. Therefore, some nonspecific 
hybridization between the nonsense CA and the target sequence was observable. This 
nonspecific binding would be reduced dramatically, and specific binding would be 
increased significantly if the non-complementary sequence in the target oligo-DNA 
would be shorter (data not shown).  
 
 
 
 
 
 
 
 
 
 
Figure 31.  Schematic structure of antisense dsRed contrast agent hybrid with 
an immobilized artificial target sequence. 
 
O
O
HN
O
rrrqrrkkr-OH
t c c g t g  a a c g g c
Gd-DOTA-Lys-FITC
 AAG TTC CAC GCG CAT CTC CCG AGG CAC TTG CCG GTG CTC AAG CTC (CH2)12 NH
CO5'
3'
= plastic 96 well plate
Chapter 3. Synthesis of PNA Conjugates 
58  
                 
Figure 32. In vitro hybridization efficacy of the PNA-CPP conjugated CAs with an 
artificial DNA target sequence 
3.2.9 In vitro biological studies on a transgenic cell line expressing dsRed 
In order to study the antisense specificity of the dsRed contrast agent in cells, a transgenic 
dsRed expressing cell line (mouse fibrosarcoma cell line expressing dsRed gene was 
kindly provided by M. Erieson, University of Minnesota) containing the target mRNA 
was incubated with dsRed CA and nonsense CA. Fluorescence studies demonstrated that 
both dsRed CA and nonsense CA enter the transgenic cells efficiently. A significantly 
higher contrast enhancement could be observed at labeling concentrations more than 1 
µM.  However, no specific accumulation of the antisense dsRed CA in comparison to the 
non-sense CA could be detected in the target containing dsRed cells. 
Fluorescence microscopy imaging of these cells showed an exclusive endosomal 
localization of the contrast agent (Figure 33). Since the target mRNA is located in the 
cytosol, the vesicular entrapment prevents a specific interaction between the CA and the 
target. Thus, further modifications of the contrast agents are required to achieve the 
release from endosomes or a direct uptake into the cytosol. 
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Figure 33. Endosomal localization of dsRed CA in dsRed expressing cells 
(Contrast agent is trapped inside the endosomes and cannot interact with target. 
dsRed CA: green (FITC fluorescence); nuclei: blue (Hoechst 33342); dsRed 
protein: red; bar represents 20 µm.) 
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3. 3 Discussion 
3.3.1 PNA synthesis and cleavage 
This chapter described the design and synthesis of two PNA-CPP conjugated MR 
contrast agents: one is an antisense contrast agent to mRNA of dsRed; while the other 
one is a nonsense contrast agent as control. They were synthesized by a continuous solid 
phase synthesis scheme. Synthetically, PNAs incorporate repetitive elements. Therefore, 
PNA synthesis is comparible to the peptide synthesis. Specifically, protecting group 
strategies, solid phase synthesis protocols, de-protection methods and purification 
procedures developed for peptide synthesis might be applicable to the synthesis of PNAs 
and their analogs with only slight modifications. However, some key notes should be 
emphasized in the synthesis of PNAs:   
1) The chemical structures of PNA monomers are much more complex than amino acid 
residues. In order to avoid interactions, such as steric hindrance effect, between 
growing PNA chains that can terminate the synthesis, we started the synthesis by 
downloading the capacity of the resin. Since the Wang resin, which is commercially 
available from Novabiochem Company, usually have high substitutions (0.5-
0.6mmol/g), it is necessary to download their substitutions to the range between 0.2-
0.3mmol/g. Kilk et al reported that the solid support should have substitution of 
between 0.01 and 0.2 mmol/g (67), and a lysine in the C-terminus of PNA improves 
PNA solubility and thus is more suitable for resin downloading than PNA monomers. 
In our synthesis scheme, D-tat peptide is synthesized on resin at first. Since Lysine is 
the second amino residue from the C-terminus of D-Tat peptide, we also downloaded 
the substitution of Wang resin by Lysine. The standard PNA EXPEDITETM column 
supplied by Applied Biosystems usually contains 2µmol per column. This is too less 
for us to be applied in our synthesis scheme. Because MRI is less sensible than 
radiolabelling imaging method, we need higher amounts for MR measurements. 
Thus, the PNA-CPP conjugated MR contrast agents should be synthesized at about 
20-30 µmol scales to ensure enough products for MR measurements. Therefore, we 
determined to synthesize PNA fragments manually on Wang resin with substitutions 
of between 0.2-0.3mmol/g. 
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2) Unlike peptides, upon Fmoc deprotection, PNA can undergo an alkaline pH-
dependent N-acyl transfer rearrangement that converts the primary N-terminus into an 
unreactive amide (87). Therefore, piperidine reactions should be carried out in precise 
controlled cycles when PNAs were synthesized manually. During our PNA synthesis 
procedure, Fmoc was deprotected by 20% piperidine in DMF in 2 x 5 min; while in 
peptide synthesis, 2 x 10 min is usually performed in Fmoc deprotection. Gallazzi et 
al. (88) suggested deprotecting Fmoc in precise 1min by 20% piperidine in DMF two 
cycles. The PNA synthesis protocol supplied by Applied Biosystems (89) suggests 
the deprotection of the Fmoc group by 20% piperidine in DMF in 2 x 2.5 min. 
However, when we tried this procedure, the Fmoc group was not completely removed 
in 2.5 min. (After aliquots of the resin-bound PNAs being cleaved and Bhoc-
deprotected with H2O/TIS/m-Cresol/ TFA (2.5:2.5:5:90) for 4 h, the products were 
checked by ESI-MS, and some of Fmoc protected products still could be observed). 
This difference might be due to the different solid supports. Wang resin is applied in 
our PNA synthesis scheme, while Fmoc-XAL PEG PS resin was used by Gallazzi and 
Applied Biosystems. Therefore, we adjusted the deprotection scheme to 2 x 5min, 
and the desired sequences could be prepared in their entirety.  
3) The exocyclic amines of the PNA monomers (A, C and G) are protected by the 
(Bhoc) protecting group. The Bhoc group can be removed with TFA in the presence 
of the scavenger m-Cresol. Thus, the cleavage cocktail for PNA is different from the 
cleavage condition for peptide. During our synthesis procedures, the cleavage cocktail 
for PNA is H2O/TIS/m-Cresol/TFA (2.5:2.5:5:90), and the cleavage condition for 
peptide is H2O/TIS/TFA (2.5:2.5:95). Actually, the cleavage cocktail of 
H2O/TIS/TFA (2.5:2.5:95) was tried in our preliminary PNA test synthesis 
experiments. It could remove the Bhoc group too. However, the water solubility of 
the product is not as good as that of the product cleft by the m-Cresol containing 
cocktail.  
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3.3.2 Determining the relaxivity of PNA conjugated contrast agents in solution and 
in labeled cells.  
The observed relaxivities of dsRed CA and nonsense contrast agents in water were 3.3 
and 5.3 (mM-1sec-1), respectively. To our best knowledge, there was no reported 
relaxivity value for the PNA-CPP conjugated MR contrast agent. Therefore, compare to 
the relaxivity of Gd(III)-DOTA complex (r1 = 4.2 mM-1sec-1 at 20MHz, 25˚C) (10), the 
observed relaxivities of dsRed CA and nonsense contrast agents are in the expected range 
for compounds with one DOTA-complexed gadolinium. However, there are some 
differences in the value of relaxivity from batch to batch of the same PNA conjugated 
Gd(III) chelates (as was observed from the contrast agents without PNA in chapter 2). 
This might be because the TFA bind with positive charged amino residue and the 
exocyclic amines of the PNA monomers as the counter-anions. The real concentration of 
these MR contrast agent were determine by the UV-Vis absorption of FITC; and 
relaxivity measurements were acquired by taking the slope of a plot of R1 versus 
concentration. Although every molecule of the CPP conjugated ligand includes one FITC 
and one ligand group, the containing of Gd(III) may be a little different. There is still 
possibility that some of the ligands have not completely chelated with Gd(III) or there 
might be some of free Gd(III) still remaining in the PNA-CPP conjugate, considering 
many donor atoms on the peptide which might offer alternative coordination sites to the 
lanthanide ion (please see the discussion in chapter 2).  
3.3.3 Intracellular uptake of PNA conjugated MR contrast agent 
Antisense PNA conjugated with different cell penetrating peptides (such as PTD-4 or 
poly-D-lysine) and radiometal complexes (such as 111In, 90Y or 64Cu) has been reported as 
nuclear imaging probes (PET and SPECT) (61, 62). The utilization of such conjugates as 
contrast agents for MR imaging is very limited, probably because the accumulation of the 
PNA imaging probes in the targeting cells could barely reach the MR detectable level. 
Heckl et al. (64) developed a MR contrast agent combining a Gd3+-complex with 
antisense PNA targeting the c-myc mRNA and the Antennapedia peptide. With this 
contrast agent, an increase in MR signal intensity and prolonged retention in tumor cells 
highly expressing this gene was observed in vitro and in vivo. But the applied 
concentration of contrast agent (0.5 mM) in that study was about 1000x higher compared 
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to the lowest concentration of dsRed CA in our experiments which is showing a 
significant increase in relaxation rate R1,cell within 3T3 cells. The difference is likely 
attributable to the different cell penetrating peptides and the Gd3+ moiety used.  Thus, our 
synthesized dsRed contrast agent has an excellent potential to be used as targeted contrast 
agent for MR imaging in cells expressing the dsRed gene.  
In order to demonstrate the antisense specificity of dsRed contrast agent, an in vitro 
binding assay was performed. After dsRed CA and nonsense CA were hybridized with 
the immobilized target oligo-DNA sequence, there is a significant higher specificity of 
the antisense dsRed CA in comparison to its nonsense counterpart. These results 
demonstrate that the antisense dsRed CA has the potential to bind specifically with its 
complementary target sequence.  
Further studies on a transgenic cell line have been performed in order to prove the 
specific accumulation in cells by targeting the mRNA. A significantly higher contrast 
enhancement could be observed at labeling concentrations above 1 µM.  However, no 
specific accumulation of the antisense dsRed CA in comparison to the non-sense CA 
could be detected in the target containing dsRed cells. Fluorescence microscopy imaging 
of these cells showed an exclusive endosomal localization of the contrast agent. Indeed, 
many studies have reported that cellular uptake of most CPP conjugates (such as Tat 
peptide or polyarginine) occurs mainly through endocytotic pathways, and most CPP 
conjugate is retained in the endosomal compartments of the cell (37). Since the target 
mRNA is located in the cytosol, the vesicular entrapment prevents a specific interaction 
between the contrast agent and the target. Thus, endosomal trapping and escape of CPP 
conjugates is one of the main rate-limiting steps which substantially limit the efficacy of 
CPP-mediated delivery of cargoes such as PNA. Therefore, further modifications of the 
contrast agents are required to achieve the release from endosomes or a direct uptake into 
the cytosol.  
Treatments with endosome disruption agents, such as chloroquine, Ca2+, sucrose or 
photosensitizers, facilitate the escape of CPP conjugates from endosomal compartments 
and their release into the cytoplasm might improve the antisense effects by two orders of 
magnitude.  Nielsen et al (90) recently summarized these protocols of CPP-mediated, 
PNA delivery-assisted endosome-disruption agents. The protocols provide efficient and 
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fairly simple methods for the cytosolic and/or nucleic internalization of antisense PNA in 
vitro. However, these protocols are unlikely to be applied in vivo. In 2006, Takeuchi et al. 
(91) reported some interesting results about the direct and rapid cytosolic delivery using 
cell penetrating peptides conjugate and pyrenebutyrate. The addition of pyrenebutyrate 
resulted in direct membrane translocation of the peptides yielding in diffuse cytosolic 
distribution within a few minutes. However, there is a limitation in this approach since it 
is not applicable in the presence of a medium or serum. The competition with various 
ionic species in the medium would hamper the interaction of the arginine with 
pyrenebutyrate.  
Additional studies are necessary for developing CPPs with better penetration properties, 
especially directly into the cytoplasmic compartment. One of the strategies is to 
incorporate endosomolytic peptides into delivery constructs (92).  Generally these are 
Asp- and Glu-rich peptides, for example, the so-called GALA peptide, that selectively 
adopt amphipathic structures when the acidic residues become protonated at the low pH 
in late endosomes, leading to membrane rupture and release to the cytoplasm. 
Polycationic polyethyleneimine (PEI) based delivery systems appear to possess intrinsic 
endosomolytic activity, although the mechanistic reasons are not well understood (35). 
The use of an influenza virus hemaglutinin derived pH-sensitive fusogenic peptides that 
destabilize lipid membranes at low pH has also been shown to ameliorate macropinosome 
entrapment of Tat protein fusion constructs (93).  
Referred from these studies, we now try to modify D-Tat49-57 with pyrenebutyrate or 
endosomolytic peptide GALA to achieve the cytosolic delivery.  A series of novel 
compounds, which covalently link Tat peptide with one or more copy of pyrenebutyrate 
residues or GALA peptide, has been designed and synthesized; further screening tests are 
under progress.   
The fact that the pAntp CPP vector can enhance endosomal escape of cationic 
polymethacrylate-DNA complexes indicates that at least some CPPs also possess innate 
endosomolytic activity (94). Some members of our group are currently working on 
developing new and novel CPPs towards achieving this goal. Their preliminary results 
demonstrate that leakage from endosomes or a direct uptake into the cytoplasm is 
achievable (Deepti Jha, et al. personal communication).  
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3.3.3 Antisense imaging by MRI 
As summarized by Weissleder (63), the major prerequisites for visualizing specific 
molecules or molecular mechanisms in vivo include: i) the availability of stable, nontoxic 
and high-affinity probes; ii) the ability of these probes to overcome biological delivery 
barriers; iii) the use of amplification strategies to increase the signal to background ratio; 
and iv) the availability of fast and high-resolution imaging techniques. Regarding these 
prerequisites, our proposal to image mRNA transcription by MRI using antisense PNA-
CPP conjugated MR contrast agents, is rational:  
First, MRI offers excellent three-dimensional spatial resolution, complete body coverage, 
and the opportunity to determine additional physiologic parameters noninvasively which 
has the ability to combine both functional and morphological imaging (2, 3). All these 
characterize MRI to contain considerable potential for molecular imaging.  
Second, PNA is a leading agent among ‘third generation’ antisense and antigene agents. 
It is extremely stable in biological fluids.  PNA oligomers with mixed bases sequences 
form duplexes (by Watson-Crick base-pairing) with complementary DNA and RNA with 
higher thermal stability than corresponding DNA-DNA or DNA-RNA complexes and 
without sacrificing sequence specificity (59). Actually, our PNA-DNA binding assay 
confirmed that there is a significant higher specificity of the dsRed antisense contrast 
agent in comparison to its nonsense counterpart. 
Third, our synthesized PNA conjugated contrast agents are very efficient to overcome 
cell membrane. A subtoxic labeling concentration of 0.5 µM is sufficient to enhance MR 
imaging contrast significantly.  
Therefore, we are making considerable progress in the development of antisense MR 
contrast agent, despite its obvious complexities. Unfortunately, antisense technology is 
proving to be much more complicated and challenging than was expected. There are still 
two main concerns regarding the antisense MR imaging: namely that the mechanism of 
localization may not be suitable for antisense interaction and that the degree of 
accumulation will be impractically low for imaging. The first concern about the 
localization of contrast agent has been discussed earlier (in the discussion of the 
intracellular uptake of PNA conjugated MR contrast agent), and our group is currently 
working on developing novel CPPs towards achieving this goal. As to the second 
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concern, there are some inspiring studies about the specific accumulation of antisense 
probes in recent years. Hnatowich et al. (95) reported the statistically significantly higher 
accumulations of antisense DNAs in cancer cells compared to control DNAs. From cell 
culture results such as using the number of cells per well and the known specific activity 
of the radiolabeled DNA, it may be calculated that the specific accumulation (i.e. 
antisense minus control DNA) is approximately 105-106 antisense DNA molecules per 
cell after 10-24hrs of incubation (and corresponds to an increase in concentration of 
antisense oligomers from nM in the media to mM concentration in the cytoplasm). These 
specific accumulations are many orders of magnitude over the steady-state target mRNA 
concentrations that are usually assumed to be in the range of 1-1000 copies per cell. One 
approach that may result in increased specific accumulation is to consider the mRNA 
target. It has been suggested that the antisense DNA may be acting in some manner to 
preserve its target mRNA (e.g. PNA do not activate RNAse H degradation of mRNA 
(59)). If so, the mRNA turnover rate would be more important for successful targeting 
than the steady-state mRNA level as an increased transcription rate would increase the 
cellular concentration of the target mRNA if stabilized by the antisense DNA or PNA. If 
this hypothesis is correct, an increased accumulation of antisense DNA or PNA may be 
expected as the number of target mRNAs increase while accumulations in non-target 
tissues would presumably remain unchanged.  
Very recently, Liu et al. (96) reported some very interesting results about antisense 
imaging of cerebral mRNA transcripts in live animals. They coupled SPIONs to 
phosphorothioate-modified oligo-DNA (sODN) with sequence complementary to c-fos 
and β–actin mRNA. In animals that were administered SPION-cfos and amphetamine, 
retention of the antisense probes was significantly elevated in the nucleus accumbens, 
striatum, and medial prefrontal cortex of the forebrain. Control groups that received a 
SPION conjugate with a random sequence probe showed no retention. This study 
demonstrated that SPION-sODN conjugates can detect active transcriptions of specific 
mRNA in living animals by MRI.  
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3.4. Outlook 
Antisense imaging mRNA transcription by MRI, which promises that any tissue with a 
unique gene expression can be specifically visualized in vivo, is an outstanding important 
subject in molecular imaging. If antisense imaging were to achieve even a fraction of its 
promise, the results could well lead a revolution in diagnostic medicine. It has been more 
than 10 years since the first molecular imaging with a tumor-targeting antisense radio-
probe was performed in an animal model of cancer. Progress in this area has been limited 
by formidable challenges of surmounting biological barriers to detect low concentrations 
of target mRNA. However, numerous recent advances, such as new antisense analogues, 
novel drug delivery technologies and better understanding of the antisense mechanism, 
offer a renewed anticipation that real-time, in vivo antisense imaging will be widely 
demonstrated. Further modifications of our antisense PNA conjugated MR contrast 
agents are needed to meliorate their targeting character, such as: 1) covalently link  
peptide vector with endosomolytic peptide or compounds, or developing novel CPPs to 
enhance the cytosolic delivery. 2) multistep labeling or pretargeting schemes which link a 
macromolecular contrast agent (Gd nanoparticles or dendrimers, etc) with CPP to 
increase MR contrast. Thus, the antisense PNA conjugated MR contrast agent will 
become a powerful tool for the molecular imaging of endogenous gene expression.  
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3.5 Summary  
1. Two MR contrast agents, conjugated to PNA and cell penetrating peptide, were 
synthesized by a continuous solid phase synthesis scheme and characterized by ESI-MS. 
2. The intracellular uptake was confirmed by fluorescence absorption spectroscopy, 
transmission fluorescence microscopy and MR imaging on NIH/3T3 mouse fibroblasts as 
well as on transgenic dsRed cells.  
3. Concentration-dependent uptake (most probably by endocytosis) was observed. A 
subtoxic labeling concentration of 0.5 µM is sufficient to enhance significantly MR 
imaging contrast.  
4. The intracellular content of Gd(III) was calculated according the relaxivity of Gd(III) 
in cell lysates. The resulting intracellular Gd(III) contents are at the range of 10-9~10-8 
mol Gd/107 cells. The intracellular relaxivity of dsRed CA is 2.5 ± 0.3 mM-1sec-1. 
5. An in vitro PNA-DNA binding assay confirmed that there is a significant higher 
specificity of the dsRed antisense contrast agent in comparison to its nonsense 
counterpart. 
6. Further studies on the transgenic cell line expressing the target mRNA showed a 
significantly higher contrast enhancement at labeling concentrations above 1 µM.  
However, no specific accumulation of the antisense dsRed CA in comparison to the 
nonsense CA could be detected in the target containing dsRed cells. 
7. Fluorescence microscopy studies have shown an exclusive endosomal localization of 
the contrast agents. Since the target mRNA is located in the cytosol, the vesicular 
entrapment prevents a specific interaction between the CA and the target. Thus, further 
modifications of the contrast agents are required to achieve the release from endosomes 
or a direct uptake into the cytosol. 
In conclusion, the synthesized PNA conjugated contrast agents are very efficient to label 
cells for MR as well as fluorescent imaging.  
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Chapter 4. Experimental  
4.1 General 
All reagents were HPLC or peptide synthesis grade. DMF, DCM, ACN, TFA, methanol, 
and FITC were obtained from Acros Organics (Heidelberg, Germany). All standard, 
protected Fmoc amino acid derivatives, 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluoro-phosphate (HBTU), pre-loaded Wang resin and 1-
hydroxybenzotriazole (HOBt) were obtained from Novabiochem (Nottingham, UK). All 
Fmoc/Bhoc protected monomers and 2-(1-H-7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HATU) for PNA synthesis were obtained from 
Applied Biosystems (Darmstadt, Germany). 1,4,7,10-tetraazacyclododecane (cyclen) was 
obtained from Strem Chemicals (Newburyport, USA). 
Analytical and semipreparative RP-HPLC was performed at room temperature on a 
Varian PrepStar Instrument (Australia) equipped with PrepStar SD-1 pump heads. UV 
absorbance was measured using a ProStar 335 photodiode array detector at 260 nm. A 
Varian Polaris C18-Ether column (4.6 × 250 mm, particle size 5 µm, particle pore 
diameter 100 Å) was used for analytical RP-HPLC. For semipreparative HPLC, a Varian 
Polaris C18-Ether column (21.2 × 250 mm, 5 µm, 100 Å) was used.  
CPP and PNA conjugates were analyzed using a linear gradient of water (0.1% TFA) 
(solvent A)/ACN (0.1% TFA) (solvent B) from 10% B to 90% B within 30 min (flow 
rate: 1 ml/min). 
CPP and PNA conjugates were purified by semi-preparative RP-HPLC. Gradient systems 
were adjusted according to the elution profiles and peak profiles obtained from the 
analytical HPLC chromatograms. 
ESI-MS was performed on ion trap SL 1100 system (Agilent, Germany). 
 
4.2 Synthesis of CPP conjugated, dual-labeled Gd(III)-based MR contrast agents 
Peptide synthesis was performed by solid-phase Fmoc/tBu-chemistry using a Heidolph 
Synthesis 1 synthesizer (Schwabach, Germany). Wang resin was used as a solid support 
at a substitution level of 0.50-0.60 mmol/g. The side chain of Arg was Pbf protected, Gln 
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was Trt protected, and Tyr was tBu protected. Fmoc-protected amino acids (four-fold 
excess) were activated in situ by HBTU/HOBt. The Fmoc protecting group was removed 
by 20% piperidine in DMF. The resin was washed with DMF after each coupling and 
deprotection step. All chemical steps were followed by a Kaiser test on the resin (97), and 
the resulting colorimetric reaction indicated the presence of free primary amines after 
Fmoc deprotection and the absence of primary amines after the coupling steps. 
 
4.2.1 Gd-DTPA-Lys(FITC)-L-Tat49-57-OH (1) 
L-Tat49-57 peptide synthesis was performed manually by solid-phase Fmoc/tBu-chemistry 
using a Heidolph Synthesis 1 synthesizer. Polystyrene-based Wang resin containing an 
Fmoc protected arginine residue (0.2g, 0.58 mmol/g) was swolled in DCM for 30 min 
and washed four times with peptide synthesis grade DMF. The resin was treated twice 
with a solution of 20% piperidine (3mL) in DMF for 10 min, and was washed four times 
with DMF. In a separate vial, Fmoc protected amino acid (4eq), HBTU (3.6eq), HOBt 
(3.6eq) were dissolved in DMF (2mL), and DIEA (8eq) was added. The resulting solution 
was added to the resin and allowed to react under N2 for 30 min. The resin was drained 
and rinsed for times with DMF. This procedure was repeated until a Fmoc protected 
Tat49-57 peptide (amino sequence: RKKRRQRRR) bound to Wang resin was obtained. An 
aliquot of the resin-bound peptide was deprotected the Fmoc group with 20% piperidine, 
and cleaved with H2O/TIS/TFA; ESI-MS analysis was performed to confirm that the 
observed masses m/z = 670.5 ((M+2H)2+), 447.5 ((M+3H)3+), 335.9 ((M+4H)4+), and 
268.9 ((M+5H)5+) were consistent with the calculated molecular weight (1339.6) of the 
Tat peptide.  
The resin-bound peptide was deprotected with piperidine, coupled with one Fmoc-
Lys(Dde)-OH residue. After additional deprotection with piperidine, DTPA dianhydride 
(4eq) was coupled on the α-NH2 group of Lys under base catalysis of DIEA (8eq). The 
resin was drained and rinsed four times with DMF. An aliquot of the resin-bound DTPA-
Lys(Dde)-Tat was cleaved with H2O/TIS/TFA; ESI-MS analysis was performed to 
confirm that the observed masses m/z = 1004.6 ((M+2H)2+), 670.0 ((M+3H)3+) were 
consistent with the calculated molecular weight (2007.31) of the DTPA-Lys(Dde)-Tat-
OH. 
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The resin-bound DTPA-Lys(Dde)-Tat was treated twice with hydrazine hydrate (2% in 
DMF, 2 min) to remove the Dde group. Then FITC was reacted with the ε-NH2 group of 
Lys (resin:FITC:DIEA= 1:4:8) within 7 hours. The solvent was removed and the resin 
was washed with DMF, DCM and methanol alternatively four times. After dried under 
vacuum, DTPA-Lys(FITC)-L-Tat-OH was cleaved off the resin using TFA/TIS/H2O 
(95:2.5:2.5, v/v/v). Crude products were precipitated by adding cold MTBE. The 
precipitated product was collected by centrifugation and exposed to the TFA cleavage 
cocktail (TFA/TIS/H2O (95:2.5:2.5, v/v/v)) for 10h. After precipitated again in cold 
MTBE, the product was collected by centrifugation and dissolved in tBuOH/H2O (4:1, 
v/v) and lyophilized. The sample was analyzed on an analytical column with detection at 
UV 218nm, using a water (0.1% TFA) (solvent A)/ACN (0.1% TFA) (solvent B) gradient 
from 10% B to 90% B within 30 min (flow rate: 1 ml/min). And then, DTPA-Lys(FITC)-
L-Tat-OH was purified by semi-preparative RP-HPLC. Gradient systems were adjusted 
according to the elution profiles and peak profiles obtained from the analytical HPLC 
chromatograms. The ligand DTPA-Lys(FITC)-L-Tat49-57-OH was characterized by ESI-
MS.  Detected molecular ions at m/z = 1117.0 ((M+2H)2+), 745.1 ((M+3H)3+), 559.1 
((M+4H)4+), and 461.7 ((M+5H)5+) were consistent with the calculated mass of the 
desired product (2232.13). 
The purified product was dissolved in 5 mL H2O, one equivalent of GdCl3.6H2O was 
added, and the pH was adjusted to 6.5 with 1N NaOH. The reaction mixture was stirred 
at room temperature for 24h. The pH was periodically checked and adjusted to 6.0-7.0 
using a solution of 1N NaOH and 1N HCl as needed. The mixtures were purified first by 
HPLC using a water (0.05% TFA) (solvent A)/ACN (0.05% TFA) (solvent B) gradient to 
separate the unstable bound Gd3+. Afterwards, the product was dialyzed (Float-A-Lyzer, 
cellulose ester membranes, MWCO: 1,000; Spectrum Laboratories, Inc.) to remove 
inorganic impurities. The solution was lyophilized and yellow to orange solids were 
obtained. The absence of free Gd3+ was checked with xylenol orange indicator. Finally, 
the product Gd-DTPA-Lys(FITC)-L-Tat-OH (1) was characterized by ESI-MS. Detected 
molecular ions at m/z = 796.6 ((M+3H)3+), 597.4 ((M+4H)4+), 478.3 ((M+5H)5+), and 
398.9 ((M+6H)6+) were consistent with the calculated mass of the desired product 
(2385.02) (Figure 34). 
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Figure 34. Chemical structure of Gd-DTPA-Lys(FITC)-L-Tat-OH (1) 
4.2.2 Gd-DTPA-Lys(FITC)-D-Tat57-49-OH (2)  
2 was synthesized with the same synthesis scheme as 1, substituting the L-form of amino 
acid residues to the D-form and reversing the amino acid sequence. Therefore the amino 
acid sequence in 2 is rrrqrrkkr. The ligand DTPA-Lys(FITC)-D-Tat57-49-OH was 
characterized by ESI-MS.  Detected molecular ions at m/z = 1117.1 ((M+2H)2+), 745.3 
((M+3H)3+), 559.0 ((M+4H)4+), and 461.5 ((M+5H)5+) were consistent with the 
calculated mass of the desired product (2232.13). 
 After chelated with Gd3+, the final product was characterized by ESI-MS also. Detected 
molecular ions at m/z = 796.3 ((M+3H)3+), 597.4 ((M+4H)4+), 478.2 ((M+5H)5+), and 
398.8 ((M+6H)6+) were consistent with the calculated mass of the desired product 
(2385.02) (Figure 35). 
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Figure 35. Chemical structure of Gd-DTPA-Lys(FITC)-D-Tat57-49-OH (2) 
4.2.3 Gd-DTPA-Lys(FITC)-Orn-D-Tat57-49-OH (3)  
3 was synthesized with the same synthesis scheme as 2, substituting the amino acid 
residue Gln by Orn. Therefore the amino acid sequence in 3 is rrrorrkkr. The ligand 
DTPA-Lys(FITC)-Orn-D-Tat57-49-OH was characterized by ESI-MS.  Detected molecular 
ions at m/z = 740.4 ((M+3H)3+), 555.2 ((M+4H)4+), and 444.6 ((M+5H)5+) were 
consistent with the calculated mass of the desired product (2218.50).  
After chelated with Gd3+, the final product was characterized by ESI-MS also. Detected 
molecular ions at m/z = 791.5((M+3H)3+), 593.9 ((M+4H)4+), 475.3 ((M+5H)5+), and 
396.2 ((M+6H)6+) were consistent with the calculated mass of the desired product 
(2371.04) (Figure 36).  
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Figure 36. Chemical structure of Gd-DTPA-Lys(FITC)-Orn-D-Tat57-49-OH (3) 
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4.2.4 Gd-DTPA-Lys(FITC)-NLS-OH (4)  
4 was synthesized with the same synthesis scheme as 1. The amino acid sequence in 4 is 
PKKKRKV. The ligand DTPA-Lys(FITC)-NLS-OH was characterized by ESI-MS.  
Detected molecular ions at m/z = 889.1 ((M+2H)2+), 592.9 ((M+3H)3+), and 
445.2((M+4H)4+) were consistent with the calculated mass of the desired product 
(1776.02). 
 After chelated with Gd3+, the final product was characterized by ESI-MS also. Detected 
molecular ions at m/z = 964.4((M+2H)2+), 643.8 ((M+3H)3+), and 483.0 ((M+4H)4+) were 
consistent with the calculated mass of the desired product (1928.76) (Figure 37). 
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Figure 37. Chemical structure of Gd-DTPA-Lys(FITC)-NLS-OH (4) 
 
4.2.5 Gd-DTPA-Lys(FITC)-PTD-4-OH (5) 
 5 was synthesized with the same synthesis scheme as 1. The amino acid sequence in 5 is 
YARAAARQARA. The ligand DTPA-Lys(FITC)-PTD-4-OH was characterized by ESI-
MS.  Detected molecular ions at m/z = 1049.6 ((M+2H)2+), 700.2 ((M+3H)3+), 525.3 
((M+4H)4+), and 420.4 ((M+5H)5+) were consistent with the calculated mass of the 
desired product (2097.23). 
 After chelated with Gd3+, the final product was characterized by ESI-MS also. Detected 
molecular ions at m/z = 750.8 ((M+3H)3+), 563.3 ((M+4H)4+) and 450.8 ((M+5H)5+),were 
consistent with the calculated mass of the desired product (2249.81) (Figure 38). 
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Figure 38. Chemical structure of Gd-DTPA-Lys(FITC)-PTD-4-OH (5) 
4.2.6 Synthesis of 4,7,10-tricarboxymethyl-tert-butyl ester 1,4,7,10-tetraaza 
cyclododecane-1-acetate (DOTA-(tBu)3)  
Please see reference (98) for the details of synthesis DOTA-(tBu)3. In brief:   
(1)1,4,7,10-tetraazacyclododecane-1-carboxymethyl-benzylester (D1): To a stirred 
solution of 1,4,7,10-tetraazacyclododecane (cyclen) in acetonitrile  was added dropwise 
benzyl bromoacetate (0.5eq.) in acetonitrile. Reaction completed at room temperature for 
2h.  
(2)1,4,7,10-tetraazacyclododecane-4,7,10-tricarboxymethyl-tert-butylester-1-
carboxymethyl-benzylester (D2): To a stirred solution of D1 in acetonitrile K2CO3 (4eq.) 
was added followed by the dropwise addition of tert-butyl bromoacetate (4eq.) in 
acetonitrile within 30 min. Reaction completed at room temperature for 48 h.  
(3) 4,7,10-tricarboxymethyl-tert-butyl ester 1,4,7,10-tetraazacyclododecane-1-acetate 
(D3): Pd/C (10% Pd) was added to a solution of D2 in MeOH, and hydrogenation was 
conducted for 4h at normal pressure. The catalyst was removed by filtration through 
Celite. The solvent was removed by a rotary evaporator. The resulting yellowish oil was 
purified by column chromatography (silica gel, 10% MeOH in DCM) to afford the 
product D3. ESI-MS (+): calcd C28H52N4O8: m/z 572.38; found 573.3 (M+H)+; 595.3 
(M+Na)+. 
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4.2.7 Gd-DOTA-Lys(FITC)-L-Tat49-57-OH (6)  
L-Tat49-57 peptide was synthesized as described above. Then the resin-bound peptide was 
deprotected with piperidine, and coupled with one Fmoc-Lys(Dde)-OH residue. After 
deprotection with piperidine, DOTA tris(tert-butyl) ester was coupled on the α-NH2 
group of Lys (coupling condition: DOTA-(tBu)3 : HATU : DIEA = 4: 3.6: 8).  The resin 
was drained and rinsed four times with DMF. The resin-bound DTPA-Lys(Dde)-Tat was 
treated twice with hydrazine hydrate (2% in DMF, 2 min) to remove the Dde group. Then 
FITC was reacted with the ε-NH2 group of Lys (resin:FITC:DIEA= 1:4:8) within 7 hours. 
Further procedures including the cleavage, HPLC analysis and purification are 
progressed the same as for (1). The ligand DOTA-Lys(FITC)-L-Tat57-49-OH was 
characterized by ESI-MS.  Detected molecular ions at m/z = 748.6 ((M+3H)3+), 561.9 
((M+4H)4+), 449.8 ((M+5H)5+), and 374.9 ((M+6H)6+) were consistent with the 
calculated mass of the desired product (2244.56).  
The ligand DOTA-Lys(FITC)-L-Tat57-49-OH was dissolved in 5 mL H2O, one equivalent 
of GdCl3.6H2O was added, and the pH was adjusted to 6.5 with 1N NaOH. The reaction 
mixture was stirred at 60˚C for 12 h. The pH was periodically checked and adjusted to 
6.0-7.0 using a solution of 1N NaOH and 1N HCl as needed. The mixtures were purified 
first by HPLC using a water (0.05% TFA) (solvent A)/ACN (0.05% TFA) (solvent B) 
gradient to separate the unstable bound Gd3+. Afterwards, the product was dialyzed 
(Float-A-Lyzer, cellulose ester membranes, MWCO: 1,000; Spectrum Laboratories, Inc.) 
to remove inorganic impurities. The solution was lyophilized and yellow to orange solids 
were obtained. The absence of free Gd3+ was checked with xylenol orange indicator. 
After chelated with Gd3+, the final product was characterized by ESI-MS. Detected 
molecular ions at m/z = 800.1((M+3H)3+), 600.3 ((M+4H)4+), 480.6 ((M+5H)5+), and 
400.4 ((M+6H)6+) were consistent with the calculated mass of the desired product 
(2397.08) (Figure 39).  
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Figure 39. Chemical structure of Gd-DOTA-Lys(FITC)-L-Tat57-49-OH (6) 
4.2.8 Gd-DOTA-Lys(FITC)-D-Tat57-49-OH (7)  
7 was synthesized with the same synthesis scheme as 6, substituting the L-form of amino 
acid residues by the D-form and reversed the amino acid sequence. Therefore the amino 
sequence in 7 is rrrqrrkkr. The ligand DOTA-Lys(FITC)-D-Tat57-49-OH was 
characterized by ESI-MS.  Detected molecular ions at m/z = 748.6 ((M+3H)3+), 561.9 
((M+4H)4+), 449.8 ((M+5H)5+), and 374.9 ((M+6H)6+) were consistent with the 
calculated mass of the desired product (2244.56). After chelated with Gd3+, the final 
product was characterized by ESI-MS also. Detected molecular ions at m/z = 
800.7((M+3H)3+), 600.4 ((M+4H)4+), 480.5 ((M+5H)5+), and 399.3 ((M+6H)6+) were 
consistent with the calculated mass of the desired product (2397.08) (Figure 40).  
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Figure 40. Chemical structure of Gd-DOTA-Lys(FITC)-D-Tat57-49-OH (7) 
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4.2.9 Gd-DOTA-Lys(FITC)-Orn-D-Tat57-49-OH (8) 
 8 was synthesized with the same synthesis scheme as 7, substituting the amino acid 
residue Gln by Orn. Therefore the amino sequence in 8 is rrrorrkkr. The ligand DOTA-
Lys(FITC)-Orn-D-Tat57-49-OH was characterized by ESI-MS.  Detected molecular ions at 
m/z = 744.3 ((M+3H)3+), 558.3 ((M+4H)4+), and 447.0 ((M+5H)5+) were consistent with 
the calculated mass of the desired product (2229.21). After chelated with Gd3+, the final 
product was also characterized by ESI-MS. Detected molecular ions at m/z = 
796.2((M+3H)3+), 596.5 ((M+4H)4+), 477.7 ((M+5H)5+), and 398.4 ((M+6H)6+) were 
consistent with the calculated mass of the desired product (2383.10) (Figure 41).  
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Figure 41. Chemical structure of Gd-DOTA-Lys(FITC)-Orn-D-Tat57-49-OH (8) 
 
4.3 Synthesis of PNA-CPP conjugated MR contrast agents 
4.3.1 PNA synthesis  
Syntheses of dsRed-PNA (tcc gtg aac ggc) and nonsense PNA (gtt cag agt cta) were 
performed in continuous solid phase synthesis after coupling of an AEEA spacer to the 
D-Tat57-49 bound on Wang resin (Scheme-4). The synthesis protocol of D-Tat57-49 and 
coupling of AEEA spacer is the same as peptide synthesis. Fmoc/Bhoc chemistry was 
used with the following PNA monomers: Fmoc-A(Bhoc)-OH, Fmoc-C(Bhoc)-OH, 
Fmoc-G(Bhoc)-OH, and Fmoc-T-OH. Each cycle of elongation consisted of (1) Fmoc 
deprotection with 20% piperidine in DMF for 2 cycles of 5 min at room temperature, (2) 
washing with DMF, DCM, and twice with NMP for 1min each at room temperature, (3) 
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coupling using a molar ratio of resin/monomer/HATU/DIEA/2,6-lutidine = 
1.0:3.0:2.7:3.0:4.5; 3 min on preactivation followed by 30 min coupling at room 
temperature, (4) capping with 2 mL of 5% acetic anhydride/6% 2,6-lutidine in DMF for 5 
min at room temperature, and (5) washing with NMP, DCM, and twice with DMF for 1 
min each at room temperature. All chemical steps were followed by a Kaiser test on the 
resin, and the resulting colorimetric reaction indicated the presence of free primary 
amines after Fmoc deprotection and the absence of primary amines after the coupling and 
capping steps. After 3, 6, 9, and 12 cycles, aliquots of the resin-bound PNAs were 
cleaved and Bhoc-deprotected with H2O/TIS/m-Cresol/ TFA (2.5:2.5:5:90) for 4 h, and 
ESI-MS analysis was performed to confirm that the observed masses were consistent 
with the calculated molecular weights of the Fmoc-protected intermediates. 
 
 
Fmoc deprotect
20% peperidine in DMF
2x 5min
Wash 2x with DMF
          2x with DCM
          2x with NMP
Activate and couple
3 eqPNA monomer, 3 eq HATU,
3 eq DIEA, 4.5eq lutidine
 in DMF/NMP (2/1) for 30 min
Wash 4x with DMF
D-Tat peptide- Wang resin
Swelled with DCM for 30 min
Cleave and deprotect
Fmoc-AEEA-D-Tat peptide- Wang resin
Fmoc-AEEA-OH
HATU, DIEA, DMF
 
 
Scheme-4. PNA synthesis cycle 
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4.3.2 Conjugate DOTA tris(tert-butyl) ester (DOTA-(tBu)3) with PNA-CPP 
conjugates 
The resin-bound PNA-CPP conjugates were deprotected with 20% piperidine in DMF, 
and coupled with one Fmoc-Lys(Dde)-OH residue. After Fmoc deprotection with 
piperidine, DOTA tris(tert-butyl) ester was coupled on the α-NH2 group of Lys.  
4.3.3 Labeling PNA-CPP conjugate with FITC  
The resin-bound DOTA-(tBu)3-Lys(Dde)-PNA was treated with hydrazine hydrate (2% 
in DMF, 2 min) to remove the Dde group. Then FITC was reacted with the ε-NH2 group 
of Lys (resin:FITC:DIEA= 1:4:8) within 12 hours.  
The PNA-peptide conjugates were cleaved off the resin using TFA/m-Cresol/TIS/H2O 
(90:5:2.5:2.5, v/v/v). Crude products were precipitated by adding cold diethyl ether. The 
precipitated product was collected by centrifugation and re-suspended in cold diethyl 
ether. After purified by semi-preparative reversed-phase HPLC, the products were 
lyophilized to give yellow powders.  The products were characterized by ESI-MS: for 
anti-dsRed PNA conjugate, detected molecular ions at m/z = 1126.3 ((M+5H)5+), 938.9 
((M+6H)6+), 805.0 ((M+7H)7+), and 704.3 ((M+8H)8+) were consistent with the 
calculated mass of the desired product (5628.2). For nonsense PNA conjugate, detected 
molecular ions at m/z = 1129.1 ((M+5H)5+), 941.1 ((M+6H)6+), 806.9((M+7H)7+), and 
706.1 ((M+8H)8+) were consistent with the calculated mass of the desired product 
(5642.4).  
4.3.4 Chelating with gadolinium 
The PNA-CPP conjugated ligand was dissolved in 5 mL H2O, one equivalent of 
GdCl3.6H2O was added, and the pH was adjusted to 6.5 with 1N Na2CO3. The reaction 
mixture was stirred at 60˚C for 12 h. The pH was periodically checked and adjusted to 
6.0-7.0 using a solution of 1N Na2CO3 and 1N HCl as needed. The mixtures were 
purified first by HPLC using a water (0.05% TFA) (solvent A)/ACN (0.05% TFA) 
(solvent B) gradient to separate the unstable bound Gd3+. Afterwards, the reaction 
mixture was dialyzed (Float-A-Lyzer, cellulose ester membranes, MWCO: 2,000; 
Spectrum Laboratories, Inc.) to remove other impurities. The solution was lyophilized 
and yellow to orange solids were obtained. The absence of free Gd3+ was checked with 
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xylenol orange indicator and by a MR based competitive ligand assay with DTPA. The 
complexes were characterized by ESI-MS: From anti-dsRed PNA complex, detected 
molecular ions at m/z = 964.7 ((M+6H)6+), 826.9 ((M+7H)7+), 723.8 ((M+8H)8+), and 
643.1 ((M+9H)9+) were consistent with the calculated mass of the desired product 
(5782.4) (dsRed CA). For nonsense PNA complex, detected molecular ions at m/z = 
1159.7 ((M+5H)5+), 966.7 ((M+6H)6+), 829.1((M+7H)7+), and 725.7 ((M+8H)8+) were 
consistent with the calculated mass of the desired product (5796.6; nonsense CA). These 
mass spectra demonstrated that the PNA-CPP conjugates were successfully chelated with 
gadolinium.  
4.4 Cellular uptake assay 
 Experiments on cells were done in 96 well microplates by inoculation of NIH/3T3 
mouse embryonic fibroblasts (1 × 104 cells/well) cultured in Dulbecco’s Modified Eagle's 
Medium (DMEM) supplemented with 10% fetal bovine serum, 4 mM L-glutamine, 100 
µg/mL streptomycin and 100 U/mL penicillin (all purchased from Biochrom AG, 
Germany). After 24 h, cells were incubated with various concentrations of MR contrast 
agents for additional 18 h. Cells were washed with Hanks’ balanced salt solution (HBSS; 
Biochrom AG, Germany) and extracellular fluorescence was quenched by incubating 
with cold trypan blue (0.05% in PBS) for 3 min followed by repeated washes with HBSS. 
Cell-related FITC fluorescence (Ex 485 nm/Em 530 nm) was evaluated in a multiplate 
reader (BMG Labtech, Germany). Subsequently, fluorescence microscopy was performed 
with the same cells on a Zeiss Axiovert 200 M (Germany), to observe the cellular 
localization (Figure 42). Instead of the first washing, cells could be incubated with 
Bisbenzimid 33342 (Hoechst 33342), a nuclear stain, for 30 min prior to trypan blue 
quenching. This can be used as counterstaining of the cell nuclei as well as for the 
evaluation of cytotoxicity, since the fluorescence (Ex 360 nm/Em 485 nm) is proportional 
to the cell number. 
In some of the first experiments, evaluation of cytotoxicity was done by addition of 
propidium iodide (PI) and a detergent with subsequent fluorescent reading (Ex 530 
nm/Em 645 nm). By combination of the two fluorescence readings FITC and Hoechst or 
PI, a correlation is established between the FITC fluorescence and the total cell number 
per well. Both methods have given quantitatively the same results, only that the absolute 
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values of the corrected FITC fluorescence are lower in the case of PI (see Figure 22/24). 
Experiments were run at least three times for each concentration with six replicates. 
Statistical analysis was performed by Student´s t-test or ANOVA with Dunnett’s post 
test. P values < 0.05 were considered significant. 
Experimental protocol on mouse fibrosarcoma cell line expressing dsRed gene was 
similar to that of NIH/3T3 mouse embryonic fibroblasts. But the culture medium of 
dsRed cell line was changed to NCTC135 supplemented with 10% DonorHouse serum 
instead of DMEM culture medium supplemented with 10% fetal bovine serum for 
NIH/3T3 cell line.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. Experimental protocol for fluorescence studies 
4.5 Determination of intracellular Gd3+ content 
Exponentially growing 3T3 cells were labeled with 0.1 – 2.5 µM PNA-CPP-CA in 175 
cm2 tissue culture flasks for 18 h. After repeated washes with Hanks’ buffered saline, 
cells were trypsinized, centrifuged and re-suspended in 1.5 mL Eppendorf tubes at 1 × 
107 cells in 500 µL complete DMEM. 500 µL of 37% HCl was added and left at 120˚C 
Inoculate cells
Incubate for 24 hours 
CA + Culture 
medium 
Incubate for 18 hours 
Read fluorescence 
Washes/quenching 
Read fluorescence & 
96 well-microplates 
Microscopy 
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overnight to lyse the cells completely. Upon this treatment all Gd(III) was solubilized as 
free aquo-ion. By measuring the relaxation rates of theses solutions at 300 MHz, it is 
possible to determine its concentration according the literature (32). To prepare standard 
samples in aqueous HCl solution: different concentrations of GdCl3 prepared in 500 µL 
distilled water at first. And then 500 µL of 12M HCl was added. The resulting GdCl3 in 
6M HCl solution was heated at 120˚C overnight. To prepare standard samples in medium 
with Cells: different concentrations of GdCl3 prepared with 1 × 107 cells in 500 µL 
complete DMEM. 500 µL of 12M HCl was added and left at 120˚C overnight to lyse the 
cells completely. Standard curves were acquired by taking the slope of a plot of the R1 
relaxation rate versus concentration of Gd(III). 
4.6 In vitro test of antisense PNA hybridizing with target sequence 
The target oligo-DNA sequence (5’-CTC GAA CTC GTG GCC CAC GGA GCC CTC 
CAT GCG CAC CTT GAA GCG CAT GAA CTC CTT GAT-3’), synthesized from 
MWG-Biotech AG, was amino-modified with a C12 linker at the 5’ end. According to 
the DNA-BINDTM application guide, the oligo-DNA was coupled to DNA-BINDTM 96-
well plate (10mM phosphate buffer, pH 8.5, at 4˚C, overnight). Different concentrations 
of dsRed CA and nonsense CA were prepared in hybridizing buffer (10mM phosphate 
buffer, pH6.5). The contrast agents were co-incubated with immobilized DNA at 37˚C 
for 1h, and then at room temperature overnight. Non-binding contrast agent was washed 
out with 10mM phosphate buffer, the content of hybrid contrast agents were determined 
by ELISA measurement, according to the procedures described in literature (86).  
4.7 In vitro MR studies 
 For MR imaging of cells, exponentially growing 3T3 cells were labeled with 0.1 – 2.5 
µM PNA-CA in 175 cm2 tissue culture flasks for 18 h. After repeated washes with 
Hanks’ buffered saline, cells were trypsinized, centrifuged and re-suspended in 1.5 mL 
Eppendorf tubes at 1 x 107 cells in 500 µL complete DMEM. Cells were allowed to settle 
before making MR measurements. Tubes with medium only, cells without MR contrast 
agent, and cells re-suspended in medium containing the extracellular contrast agent 
Magnevist® (Schering, Germany) at 50 µM served as controls. 
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MR imaging of the cell pellets was performed at 300 MHz using T1- and T2-weighted 
spin-echo sequences at room temperature (~21˚C). 
The axial slice of interest was positioned through the cell pellet. Experimental parameters 
for T1 were: field of view 17 x 6.9 cm2, matrix 512 x 256, slice thickness 1.5 mm, SW 70 
kHz, TE 14.6 ms, TR 70-7000 ms, 2 averages (logarithmic time steps, 80 images). For 
T2, similar parameters were used, but TR = 10 s and TE = 15-600 ms (linear time steps, 
40 echoes). Sagittal images were obtained with a field of view 14 x 6.9 cm2, matrix 256 x 
256, slice thickness 2 mm, SW 100 kHz, TE 9.2 ms, TR 1500 ms, 26 averages for T1 
weighted images, and a field of view 14 × 6.9 cm2, matrix 256 × 256, slice thickness 2 
mm, SW 100 kHz, TE 80 ms, TR 10000 ms, 6 averages for T2 weighted images. 
Relaxivity measurements of contrast agents were performed in the concentration range of 
0 – 30 µM using the same experimental setup. CAs were diluted in water and 1ml 
aliquots were transferred to Eppendorf cups. 
To examine the dependence of the relaxivity on the magnetic field strength, additional 
T1-measurements were performed at a frequency of 123 MHz and a magnetic field of 3 T. 
For these experiments, an inversion recovery sequence was used to obtain images from a 
1 mm thick slice through the samples. The inversion time was varied from 23 ms to 3000 
ms in about 12 steps. The images were read out with a turbo spin echo technique, 
acquiring 5 echoes per scan. The repetition time TR was 10 s to make ensure complete 
relaxation between the scans. A resolution of 256 × 256 voxels over a Field-of-view of 
110 × 110 mm2 was reached. Six averages were acquired within less than 25 min. 
4.8 Data analysis  
The fitting to relaxivity curves was performed with self-written routines in MATLAB 6.5 
R13 (The Mathworks Inc.). The series of T1 and T2 relaxation data were fitted to the 
following equations: a) T1 series with varying t = TR: S = S0 (1 - a × exp(-t / T1)). b) T2 
series with varying t = TE: S = S0 exp(-t / T2) + b. Nonlinear least-squares fitting of three 
parameters S0, T1/T2, and a/b was done for each voxel with the Gauss-Newton method 
(MATLAB function nlinfit). For each fitted parameter, the 95% confidence intervals 
were calculated (MATLAB functions nlparci, nlpredci) and used as an error estimate of 
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the fitted relaxation times T1/T2 and S0 (initial signal at t = 0). The fit procedure resulted 
in parameter maps of T1, T2, S0 and corresponding error maps σT1, σT2, σS0. 
Image-regions around the tubes were defined as Regions of Interest (ROIs), and the 
means and distribution width of the relaxation times of voxels in these regions were 
calculated: An iterative Gaussian fit was used to determine mean and standard deviation 
(SD) of a distribution with outliers. For this purpose, a distribution histogram was first 
fitted to a Gaussian to estimate mean and SD. The tails of the distribution were then 
discarded by using a threshold of three SDs. A repeated fit proved to be robust and 
converged to the 'true' Gaussian mean and width of the distribution barring the outliers, 
observed as a result of the non-linear fit of noisy voxels. The processing of the relaxation 
data thus resulted in specific R1,2 = 1/T1,2 values for each tube sample including the 
standard deviation in the selected ROI ensemble. The ensemble error matched closely the 
errors of a single-voxel fit, which showed that no further systematic errors were 
introduced by the image encoding. Finally, the relaxivity r1,2 was calculated from the 
slope of R1,2(c) versus the concentration c of the contrast agent by an error-weighted 
linear regression. 
For the inversion recovery experiments at 3 T, the regions of interest were again defined 
inside the sample tubes. The values from all voxels inside each ROI were averaged; the 
resulting relaxation curves were used to fit the equation M0*(1-2·exp(-TI/T1)), using the 
nonlinear least squares technique implemented in MATLAB. 
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